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Abstract
Cell division and cell death (apoptosis) are two essential processes to main-
tain the specific number of cells in all multicellular organisms. In humans,
the misregulation of these processes leads to severe diseases, such as cancer,
and neurological, inflammatory or autoimmune diseases. Proteins are the
most versatile macromolecules in all living organisms and are the orches-
tra directors of the majority of cellular processes. Their three-dimensional
structure and the interaction with other molecules are essential for their cor-
rect biological function.
This work focus on small human protein survivin which plays an impor-
tant role in cell division and apoptosis, and has been extensively reported
in clinical research. Our aim was to discover new interaction partners of
survivin, and to study their specific binding and structure to better under-
stand its function. We successfully used microarray peptide technology to
determine new possible interaction partners and microscale thermophoresis
to confirm these interactions. The direct interaction between the shugoshin-
like protein family and survivin has been reported and highlights its impor-
tance in cell division.
In addition, this thesis exhibits the powerful multivariate Bayesian inference
approach for data analysis by focussing on addressing X-ray crystallography
problems of experimental phasing for molecular structure determination.
This approach has also been successfully applied to determine the binding
curve and to calculate the interaction strength between two molecules, and
avoids manual treatment and human subjective bias.
v

Swedish summary
Celldelning och programmerad celldöd är två viktiga processer för att
bibehålla det specifika antalet celler i alla multicellulära organismer. I män-
niskan leder missreglering av proteiner kopplade till dessa processer till al-
lvarliga sjukdomar så som cancer samt neurologiska, inflammatoriska eller
autoimmuna sjukdomar. Proteiner är de mest mångsidiga makromolekylerna
i alla levande organismer och de är dirigenter för de flesta cellulära pro-
cesserna. Deras tredimensionella struktur och interaktioner med andra
molekyler är avgörande för deras korrekta biologiska funktion.
Detta arbete fokuserar på det mänskliga proteinet survivin som spelar en
viktig roll vid celldelning och programmerad celldöd vilket det i stor om-
fattning har rapporterats om i klinisk forskning. Vårat mål var att upptäcka
nya interaktionspartners för survivin och att studera deras specifika bindning
och struktur för att bättre förstå deras funktion. Vi har framgångsrikt använt
tekniken mikromatriser för peptider för att bestämma nya möjliga interak-
tionspartners och termofores i mikroskala (MST) för att bekräfta dessa in-
teraktioner. Direkt interaktion mellan proteiner ur shugoshin-liknande pro-
teinfamiljen och survivin har rapporterats och framhäver dess betydelse vid
celldelning.
Därutöver behandlar avhandlingen även datanalysmetoden Bayesiansk statis-
tik med multivariata metoder för att lösa fasproblemet inom röntgenkristal-
lografi vid strukturbestämning av proteiner. Metoden har framgångsrikt an-
vänts för att bestämma bindningskurvan och beräkna interaktionsstyrkan
mellan två molekyler genom att undvika påverkan av manuella
tillvägagångsätt samt mänskliga subjektiva bedömningar.
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Chapter 1
Introduction
All living organisms are composed of the basic structural and functional
unit called a cell. The cell consists of water, inorganic ions and organic
molecules (carbohydrates, nucleic acids, lipid and proteins) and can be clas-
sified into prokaryotic and eukaryotic. Eukaryotic cells are more complex
than prokaryotic ones, and are characterised by presenting not only differ-
ent compartments (organelles) with specific functions, but also DNA in the
nucleus [1, 2]. They are found in more complex organisms, which may also
be multicellular like humans.
To be able to maintain the correct shape, size and functions, multicel-
lular organisms need to balance the total number of cells by two essential
physiological processes: cell division and cell death. On the one hand, cell
division increases the number of cells and allows the organism to grow. On
the other hand, cell death eliminates those cells no longer needed or are
damaged. These two processes are crucial for correct cellular balance in or-
ganisms and they should be tightly controlled or regulated [3]. In humans,
the misregulation of these processes is linked to severe diseases, such as
cancer, neurological, inflammatory and immune diseases [4, 5].
1
Chapter 1. Introduction
This thesis focuses on studying the human survivin protein, which is in-
volved in cell division and cell death regulation. As this protein has been
related to chemotherapy resistance, recurrence and bad outcome cancers, a
better understanding of its function can lead to better diagnostics and treat-
ment [6].
1.1 Protein structure and function
Proteins are one of the most important macromolecules in the cell. They
are involved in almost every cellular process and their structure is required
for both their function and the regulation of these processes. They are en-
coded in the genes present in the DNA which is transcribed into mRNA and
is translated into protein. Proteins are polymers composed of a combination
of 20 different amino acids. The amino acid sequence is specific for each
protein and determines their three-dimensional structure and function.
In eukaryotic cells, the number of synthesised proteins is much big-
ger than that of genes. This is mainly possible by two processes that oc-
cur during eukaryotic protein synthesis: alternative splicing during mRNA
maturation and post-translational modification (PTM) [7]. mRNA matura-
tion occurs at the nucleus before protein is exported to the cytoplasm to
be translated. Eukaryotic genes are present as introns and exons, which are
nucleotide sequences that carry information. During mRNA maturation, in-
trons are removed by RNA splicing and only exons are present in the final
mRNA that encodes protein. Alternative splicing allows multiple proteins
to be encoded from a gene by including some introns in matured mRNA.
These proteins are commonly called isoforms and normally present a simi-
lar function, but can also perform unique functions.
2
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PTM comprises chemical modifications introduced into proteins after
their translation in the cytoplasm. The presence of PTM in proteins plays an
important role in their function as they can be involved in their regulation,
localisation and interaction with other molecules in cellular pathways.
1.2 Protein interactions
Proteins perform their function by interacting with different molecules,
ranging from small ligands or cofactors to big complexes (e.g. proteins,
DNA, lipids, etc.). Understanding the different interactions of a protein pro-
vides relevant information about its function, regulation and role in the in-
volved cellular processes.
One of the important reasons for improving our understanding about
protein interactions and cellular pathways is the discovery of new chemicals
with a therapeutic effect (drugs) to cure the disease or reduce its symptoms
[8]. The discovery of new drugs is closely linked to protein structure and
interactions because, by knowing where molecules bind and their affinity,
more selective and efficient drugs can be developed [9]. By assuming that an
interaction between two biomolecules is rapidly reversible in an equilibrium
controlled by the law of mass action, it can be defined as follows [9]:
[A] + [B]
kon
koff
[AB]
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where:
[A] and [B] = is the concentration of the two interactions molecules,
respectively
[AB] = is the concentration of the complex
kon = is the association rate constant
ko f f = is the dissociation rate constant
Its binding affinity is defined as the strength of the interaction between
two molecules, and it is physico-chemically described as the dissociation
constant (KD) when the system is in equilibrium (Eq.1.1).
KD =
[A][B]
[AB]
=
ko f f
kon
(1.1)
The dissociation constant can be used to calculate binding free energy
by the van’t Hoff formula (Eq.1.2).
∆G = RT lnKD (1.2)
where:
R = is the universal gas constant
T = is the temperature expressed as Kelvin
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1.3 Inhibitor of Apoptosis Protein family: Survivin
The Inhibitor of Apoptosis Protein (IAP) family is a group of human
proteins that suppress programmed cell death (apoptosis) by different stim-
uli [10]. Although these proteins have several domains and functions, they
have at least one Baculovirus IAP Repeat (BIR) domain [11]. This domain
is characteristic of this family, gives its name to the genes that encode BIRC
proteins (Figure 1.1) and is important for the direct interaction between pro-
apoptotic proteins (e.g. caspases) [11, 12]. It is a globular domain that con-
sists of approximately 70 residues and binds a Zn2+ ion coordinated by three
cysteines and one histidine (CX2CX6WX3DX5HX6C) [13]. The Human
IAP family consists of eight members (cIAP1, cIAP2, XIAP, livin, ILP2,
NAIP, survivin and Apollon/BRUCE) grouped into three different classes
(Figure 1.1) depending on the presence of a RING (Really Interesting New
Gene) zinc finger domain and the homology of their BIR domains (BIR1,
BIR2 and BIR3) [14, 15].
Survivin is the smallest IAP family member and is encoded by the gene
BIRC5, located at human chromosome 17 (locus 25.3) [17, 18]. Its normal
expression is limited to developing embryos or rapidly dividing cells (e.g.
haematopoietic, epithelial or gonadal cell lines) [6, 19]. The expression of
survivin in differentiated tissues is usually linked to tumours or other dis-
eases [20, 21]. Nonetheless, other IAPs can be expressed in differentiated
tissues in normal cell lines. This protein is 16.6kDa big and presents a se-
quence of 142 amino acids. Survivin is located in the cytoplasm, the nu-
cleus and in mitochondria, and is described as a dimer by several structural
studies, including X-ray crystallography and nuclear magnetic resonance
(NMR) [22–24]. The monomer structure consists of a BIR domain (residues
1-88), a linker (residues 89-97) and an extended carboxyl-terminal α-helix
5
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Figure 1.1. Human IAP Family representation. Three Human IAP Family classes
are shown; including the proteins, genes and chromosomes that encode them. Class
1 consists of cIAP1 and cIAP2 (Cellular IAP 1 and 2), XIAP (X-linked IAP), livin
and ILP2 (IAP-like Protein 2), presents one RING zinc finger domain and can have
from one to three BIR domains in tandem. Class 2 is formed by an NAIP (Neuronal
Apoptosis Inhibitor Protein), and presents three BIR domains and the characteris-
tic NLR family domains (Nucleotide-binding Oligomerisation Domain (NOD)-like
Receptor) family. Class 3 consists of the survivin and Apollon/BRUCE (BIR Repeat-
containing Ubiquitin-Conjugating Enzyme) proteins that only contain one BIR do-
main similar to BIR1 or BIR2, depending on the classification used. The different do-
mains are: BIR (Baculovirus IAP Repeat); CARD (Caspase Recruitment Domain; in
green); LRR (Leucine-Rich Repeat; in pink); RING (Really Interesting New Gene;
in purple); UBA, (UBiquitin-Associated; in orange); UBC (UBiquitin-Conjugating;
in yellow) and NATCH (named as the protein that contains it; NAIP, C2TA, HET-E,
and TEP1; in blue). This picture was created according to the domain information
obtained from the ”Batch Web CD-Search tool from NCBI” [16].
(residues 98-142) or a coil-coil domain (Figure 1.2). Like other IAPs, sur-
vivin binds Zn2+ in its BIR domain, and this binding is coordinated by
Cys57, Cys60, His77 and Cys84 (Figure 1.2) [22,23]. The structure presents
three separate and chemically different surfaces, including acidic and basic
6
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patches in the BIR domain, as well as a hydrophobic helical cluster at the
end of the C-terminal [23]. The basic patch includes part of the BIR domain,
the linker and the beginning of the C-terminal α-helix. Part of this region
(residues 89-102) participates together with N-terminal residues (6-10) in
dimer formation. The hydrophobic cluster at the end of the C-terminal may
play an important role in the survivin interactions with other proteins (Fig-
ure 1.2) [22, 23].
Figure 1.2. Dimer survivin structure. The BIR and C-terminal domains represented
in pink and blue, respectively. The Zn2+ atoms are displayed as black spheres. At
the right top corner of the figure the coordination of the Zn2+ binding is represented.
At the right bottom corner, the molecular surface of the survivin dimer is displayed
according to the local chemical properties: acidic (red), basic (grey), polar(grey) and
hydrophobic (yellow). The figures were generated with UCSF chimera 1.11 software
[25].
Survivin is involved in several important cellular processes, including
cell division, apoptosis and the correct homeostasis of the immune sys-
tem [5, 26]. Survivin can act as a transcription factor and regulates the syn-
thesis of microRNA (non-coding short RNA molecules that provide epige-
netic biological control by regulating gene expression at post-transcriptional
7
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levels) [27]. The aberrant overexpression of survivin is tumour-related and
is indicative of diminished overall survival, higher recurrence rates and re-
sistance to therapy [6, 17, 20, 28].
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1.4 Survivin functions
1.4.1 Cell division
The cell cycle is divided into four coordinated phases that consist of two
gap phases (G1 and G2), one DNA synthesis phase (S) and the mitosis or
division phase (M) (Figure 1.3). Mitosis is also divided into various phases;
prophase, prometaphase, metaphase, anaphase and telophase, followed by
cytokinesis (Figure 1.3) [1,29]. This whole process requires tight regulation
and different checkpoints to ensure correct cell division.
Survivin plays an important role in cell division by forming part of the
chromosomal passenger complex (CPC). The CPC is formed by four pro-
teins; borealin, the inner centromere protein (INCENP), aurora kinase B
(aurora B) and one monomer of survivin [30–32]. This complex is, in turn,
divided into two modules linked by the INCENP protein: the localisation
and regulation module and the activity module. The localisation module
consists of borealin and survivin bound to the N-terminal of INCENP. The
activity module is composed of aurora B and the C-terminal of INCENP,
called IN-box, which is essential for full aurora B activity [32].
This protein complex is first observed at the nucleus in the late S phase,
and presents its higher expression in phases G2 and M. During mitosis, this
complex is localised at different levels and is involved in many different
processes. In the early prophase, the CPC is observed along chromosomal
arms and is confined to the inner centromere region in the late prophase,
prometaphase and metaphase. Its function in these phases includes, among
others; the regulation of the chromosome structure, the removal of cohesin
(a protein complex that keeps sister chromatids together) from chromosomal
arms, mitotic spindle formation, the regulation of kinetochore-microtubule
9
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attachments and the regulation of mitotic checkpoints. At the beginning of
the anaphase, the CPC moves from the inner centromere to the microtubules
of the central spindle, where it is involved in correct chromosome segrega-
tion. In the telophase, the CPC is localised in the mid-body and is involved
in the physical separation of cells [32–34].
This cellular process becomes complicated because it requires the inter-
action of many different protein families and is tightly regulated [34]. The
CPC has been described in interactions with several of these proteins, such
as the interaction with histone H3 through survivin [35–37].
The human shugoshin-like protein family also plays a key role in cell
division. It consists of two members (hSgo1 and hSgo2) and is related with
the protection of the cohesin complex that keeps sister chromatids together
before segregation [32,38,39]. Previous studies have shown that hSgol1 and
hSgol2 directly interact with the CPC and are involved in the localisation of
the CPC in centromeres [34, 40–44]. In paper III, the physical interaction
of these proteins with human survivin is demonstrated.
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Figure 1.3. A. Cell cycle. In phase G1, the cell is metabolically active and continu-
ously grows, but DNA is not duplicated. From this phase, the cell can exit the cell
cycle and go to the resting stage (Gap phase 0, G0) or can continue with cell division
and go to the phase S. DNA replication occurs in the phase S and is followed by
the phase G2, where the cell continues growing and produces the proteins needed
for division. B. Cell division or Mitosis. In the prophase, chromosomes condense
by presenting two sister chromatids linked by the centromere. In this phase, centro-
somes (microtubules organising centre, MTOC) also build a cytoskeletal structure
that is required for division, namely the mitotic spindle. In the prometaphase, the
nuclear membrane is degraded and the mitotic spindle comes into contact with chro-
mosomes. In addition, kinetochore (a complex protein structure) is associated with
the centromere of each sister chromatid, which allows the connection of sister chro-
matids with the mitotic spindle by microtubules. In the metaphase, chromosomes are
located along the equator zone of cells by microtubules. In the anaphase, sister chro-
matids are separated by a force generated by microtubules in opposite directions.
Each chromatid gives a full new chromosome. The telophase is the last phase of
mitosis, in which new chromosomes reach the mitotic spindle, the membrane is re-
stored and the cell is prepared for cell division into two cells, known as cytokinesis.
C. Chromosome structure [1, 2].
11
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1.4.2 Apoptosis
Apoptosis is a process by means of which harmed cells or those no longer
needed, are degraded by activating programmed cellular death. It is also
called programmed cell death and is essential for maintaining tissue home-
ostasis in multicellular organisms, embryo development and immune sys-
tem function [2, 45]. Apoptosis is mediated by a cysteine-aspartic protease
family called caspases, which includes caspase-3, -6, -7, -8 and -9. These
proteins are synthesised as an inactivated form (procaspase precursors) and
can be classified as initiator caspases (caspase-8 and -9) or executioner cas-
pases (caspase-3, -6 and -7). Caspases activate one another during the pro-
cess called the caspase cascade, which leads to the proteolytic cleavage of
several cellular targets and cell death. Apoptosis consists in two pathways
that can be extrinsic (initiated by an external cellular signal) and intrinsic
(initiated by an intracellular signal; e.g. cellular stress) (Figure 1.4) [46].
Misregulation in apoptosis is linked with several diseases, such as cancer
and autoimmune diseases (described in paper I) [3, 5, 45].
Survivin can inhibit both apoptosis pathways, but it cannot bind cas-
pases directly as it lacks the linker sequence upstream of the BIR domain
present in other IAPs (e.g. XIAP) [23, 24]. The interaction of survivin with
the XIAP protein enhances XIAP stability, which results in the inactivation
of caspases-3 and -9 [5, 47]. Survivin can also bind pro-apoptotic protein
Smac/DIABLO, which is an antagonist of the XIAP protein [36, 48]. This
interaction prevents the Smac/DIABLO being released from mitochondria,
and inhibits caspase activation. Structural studies have shown the interaction
of survivin with the N-terminal of Smac/DIABLO [36].
12
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Figure 1.4. Apoptosis pathways. The extrinsic pathway is activated by an external
ligand binding to the death receptor placed on the cell surface. This brings about the
activation of the intrinsic pathway and the caspase cascade, which lead to cell death.
The intrinsic pathway is also recognised as mitochondrial apoptosis and is activated
by different cellular stresses that lead to cytochrome c release from mitochondria
and the formation of apoptosome (a protein complex), which activates caspases to
cause cell death [46].
1.5 Survivin isoforms
The BIRC5 gene consists in four dominant exons (1, 2, 3 and 4) and two
cryptic exons (2B and 3B) that lead to the expression of different alterna-
tive spliced variants of survivin, as shown in Figure 1.5 [28]. Many dif-
ferent survivin isoforms have been reported, and at least six of them have
been seen to be of biological significance; survivin, survivin-2B, survivin-
∆Ex3, survivin-3B, survivin-2α and survivin-3α [28, 49]. The majority of
the mRNA expressions of the BIRC5 gene comprise survivin, survivin-2B
13
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and survivin-∆Ex3 [5].
Figure 1.5. Alternative BIRC5 splicing.
The expression of survivin isoforms has been related mainly to malig-
nant cells and is almost undetectable in normal cell lines [50–52]. While
survivin expression is constantly high expressed in several cancers, the ex-
pression of survivin isoforms is variable and depends on specific cancer
types and stages. Survivin isoforms are involved in various carcinogenic
processes, including proliferation, apoptosis and metastasis [52]. This dif-
ference in expression and its relation with tumour development and patient
survival suggest that some isoforms may have regulatory mechanisms and
might be a better marker of tumour prognostics and diagnostics [53, 54].
Survivin-2B is the longest isoform with 165 residues. It presents the
insertion of cryptic exon 2B, which interrupts the BIR domain by adding
23 residues (between the Ile74 and Gln75 residues) that affect Zn2+ bind-
ing [28]. This isoform has been located mainly in the cytoplasm, while low
14
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expression levels have been seen at the nucleus and in mitochondria [49,
55, 56]. The survivin-2B function is unclear and controversial. Some stud-
ies show that it presents pro-apoptotic activity (by promoting cell death), or
its expression is correlated inversely with tumour stages, and is more ex-
pressed in well-differentiated tumours. However, other studies reveal that
expression is related more to treatment-resistant cancer cells or to other dis-
eases (e.g. high survivin-2B expression in the serum of rheumatoid arthritis
patients) [20, 49, 57, 58].
Survivin-∆Ex3 lacks exon-3 and contains only 137 residues [59]. This
exclusion of exon-3 generates a unique carboxyl terminal that includes fea-
tures that are not present in other isoforms [28]. This terminal consists of
a mitochondrial localisation signal sequence, a nuclear localisation signal
sequence and a Bcl2 homology domain (BH2). Survivin-∆Ex3 has been
found mainly expressed in the nucleus of malignant cell lines [54, 56, 59].
The BH2 domain is characteristic of another apoptosis regulatory family,
the Bcl2 family [60], and it confers survivin-∆Ex3 a specific anti-apoptotic
function [61]. This isoform can be associated with Bcl2 (anti-apoptotic pro-
tein) and inhibits caspase-3 activity to result in apoptosis inhibition [62].
Noton et al. have demonstrated that survivin can form heterodimers with
other isoforms (survivin-2B and survivin-∆Ex3), and that these isoforms do
not play a role in either mitosis or the complex formation with the CPC
[52, 63]. The formation of survivin heterodimers might play an important
role in survivin regulation as isoforms exhibit various apoptotic properties
and can affect the apoptotic activity of survivin [20, 28, 64].
Although there are many studies about the isoforms of survivin, their
possible functions and how they interact with survivin remain to be eluci-
dated. This thesis tests initial expression and purification trials of recombi-
nant survivin-2B and survivin-∆Ex3 (Chapter 4).
15
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1.6 Scope of the thesis
This thesis focus on the characterisation and structural studies of human
survivin interactions that were used as a test system for Bayesian inference
of data analyses.
Chapter 2 describes the methodology followed in this thesis for protein
production and characterisation, protein:protein interactions, X-ray crystal-
lography and structure determination.
Chapter 3 briefly introduces the statistical inference focussing of the
Bayesian inference. The different Bayesian approaches used for the data
analyses of paper I/IV and paper III are described. Paper I and IV inves-
tigate how the Bayesian inference can improve the calculation of structure
factor differences in X-ray crystallography.
Chapter 4 focuses on the characterisation of human survivin and the in-
teraction experiments of survivin:borealin and survivin:shugoshin proteins
published in paper III. At the end of this chapter, the initial expression and
purification trials of the recombinant survivin isoforms are described.
Chapter 5 summarises the conclusions and future work.
Paper II reviews current knowledge about survivin in autoimmune dis-
eases. It describes the usefulness of survivin measures for clinical appli-
cations, and provides survivin inhibiting strategies and recent results about
survivin inhibition in modern therapies for cancer and autoimmune diseases.
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2.1 Protein production
2.1.1 Expression system
Biochemical analyses often require large amounts of pure sample (in the
order of mg). Obtaining these amounts from a natural source can be arduous
work, and is sometimes even impossible. The overexpression of recombi-
nant proteins in heterologous systems is normally used. Recombinant pro-
teins are synthesised in a cell from exogenous DNA (vector) containing the
gene of interest, generated by genetic engineering. This DNA is artificially
introduced into the cell during a process called transformation. However,
the expression of recombinant proteins can also involve problems, such as
poor host growth, the formation of inclusion bodies (non-soluble proteins),
protein inactivation, no expression, misfolding, etc [65]. These problems
can be overcome by optimising the expression conditions, changing the ex-
pression system, or even modifying the protein of interest (e.g. truncated
proteins) [66, 67].
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Many different host systems are available for recombinant protein ex-
pression (bacteria, yeast, insect cells, mammalian cells, etc.). Escherichia
coli (E. coli) bacteria have been highly used for the overexpression of many
heterologous recombinant proteins [67]. It is a prokaryotic organism that is
easy to culture and allows high cell density, does not require expensive me-
dia to grow (e.g. Luria Bertani medium, LB) and can be easily transformed
with exogenous DNA. The expression in prokaryotic cells involves certain
disadvantages like post-translational modification (PTM) (e.g. glycosyla-
tion, phosphorylation) not being included [68]. Some eukaryotic proteins
require such modifications for their correct folding and function. However,
if no knowledge is available about these requirements, it is worth attempting
overexpression in E.coli before engaging in more difficult expression hosts.
The most common E.coli expression strains present the T7 system (e.g.
DE3 strains) [67]. In their chromosomal DNA, these strains have a copy of
the phage T7 RNA polymerase gene, controlled by the lac promoter, which
allows the expression of the genes cloned downstream of the T7 promoter.
In the presence of an inducer (e.g. Isopropyl-β -D-1-thiogalactopyranoside,
IPTG), T7 RNA polymerase is expressed and allows the expression of the
gene of interest [69]. In this thesis, three different strains were used for
protein expression (One Shot BL21 Star (DE3), RossettaT M (DE3) pLysS
and Lemo21 (DE3)). They are all derivatives of the BL21 (DE3) strain,
which presents the T7 system approach and is deficient in proteases Lon
and OmpT, which allows higher protein expression [70,71]. One Shot BL21
Star (DE3) (Invitrogen, Thermo Fisher Scientific) also presents a mutation
in the RNase gene by providing greater mRNA stability and better protein
yields. RossettaT M (DE3) pLysS (Novagen-Merck) is designed to improve
eukaryotic protein expression by presenting codons that are rarely used in
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E.coli. This strain also expresses the natural inhibitor of T7 RNA poly-
merase, T7 lysozyme (pLysS), by suppressing its basal expression and sta-
bilising the vectors that encode the proteins which affect cell growth and
viability. Lemo21 (DE3) (New England BioLabs) has an extra plasmid with
the Lemo system (pLemo), which allows a tuneable expression of difficult
soluble proteins (e.g. toxic proteins). pLemo encodes the T7 lysozyme gene
controlled by a L-rhamnose inducible promoter [72, 73].
The pET expression system is the most widespread vector system used
for the expression of recombinant proteins [74]. These vectors contain the
T7 promoter and the translational signals required for protein expression
[75,76]. They might also present other features [66], such as selection mark-
ers (provide resistance to antibiotics to ensure that the vector remains inside
the cell), fusion proteins (to improve target protein solubility) [77], fusion
tags (to improve protein purification) and cleavage sites (the amino acid se-
quences recognised by proteases, e.g. thrombin or Human Rhinovirus 3C
protease (HRV3C), and are used to remove different tags after purifica-
tion) [78]. In this thesis, several pET vectors were selected to improve both
the expression and solubility of the target proteins (Table A.1).
2.1.2 Cloning and expression
The different protein target genes were commercially obtained (Thermo
Fisher Scientific) and cloned into the specific vector. Cloning was performed
with the InFusion HD Cloning kit (Clontech Takara) [81] and the new con-
structs containing the target gene were confirmed by sequencing (GATC
Biotech). Appendix A describes all the cloned genes and the used primers.
Protein expression can be performed very differently. In this thesis, ex-
pression optimisation (temperature, induction time, IPTG concentration, etc.)
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Table 2.1. pET vectors description
Vector Selection Fusion tag Cleavage Advantage
marker site
pHis8 [79] KanR 8xHis-tag Thrombin Affinity
(N-terminal) chromatography
pET28b+8His KanR 8xHis-tag Thrombin Affinity
(N-terminal) chromatography
pET29b KanR 6xHis-tag Thrombin Affinity
(C-terminal) chromatography
pWarf(-) [80] KanR eGFP protein HRV3C Fluorescence
+8His-tag (C-terminal) Affinity
chromatography
pET48b KanR Thioredoxin(TRX) HRV3C Solubility
+6xHis-tag (N-terminal) Affinity
chromatography
pET49b KanR Glutathione S HRV3C Solubility
transferase (GST) Affinity
+6xHis-tag (N-terminal) chromatography
on a small scale was done following a large-scale overexpression under the
best conditions [82]. After protein overexpression, cells were harvested, re-
suspended in lysis buffer and disrupted by a high pressure homogeniser
(EmulsiFlex-C3, Avestin).
Lysis buffer composition strongly depends on the target protein (e.g.
isoelectric point of the protein) and the chosen purification approach. Addi-
tives are often included in the lysis buffer to improve target protein stabil-
ity and solubility (e.g. salt, detergents, reducing agents, ligands, etc.) [83].
In this thesis, lysozyme, deoxyribonuclease (DNAse) and pefabloc (Sigma-
Aldrich) were always included in lysis buffers. Lysozyme is an enzyme that
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affects the bacteria cell wall and ensures the complete lysis of cells. DNAse
is an enzyme that degrades DNA and improves a sample’s viscosity. Many
different proteins are released during cell disruption, including proteases
(enzymes that degrade other proteins). Pefabloc SC (Sigma-Aldrich) is an
irreversible protease inhibitor that is added to avoid recombinant protein
degradation.
2.1.3 Protein purification
In this thesis, two-step purification was done, including affinity chro-
matography and size exclusion chromatography (SEC) [84]. Affinity chro-
matography consists of immobilising the target protein in a matrix and sepa-
rating it from the protein mixture. In immobilised metal affinity chromatog-
raphy (IMAC), the matrix is charged with metal ions, such as Ni2+ [85,86].
These metals have an affinity for those proteins by presenting poly-histidine
tags and bind them. After several wash steps to remove non-specific bind-
ings, the target protein is eluted with imidazole, which competes with the
histidine-tag for Ni2+ [85, 86]. This approach was used as the initial purifi-
cation step because it normally leads to a reasonably pure sample.
SEC separates proteins into their molecular weights, where the larger
the protein, the faster elution becomes. This approach can be used to re-
move different sized impurities, and to analyse the protein’s homogeneity
and oligomerisation state [87]. This chromatographic step is commonly used
as a final purification step.
In some techniques, the presence of tags can affect the results, and
they are sometimes removed after purification [78]. For example in pro-
tein crystallography, the presence of tags can increase the protein disorder
level, which makes it more difficult to crystallise. Reverse chromatography
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was also used to remove purification tags and fusion proteins after cleav-
age. IMAC was used to bind the free histidine-tags and fusion proteins or
proteases that also contain histidine-tag [86]. The free-tag target protein is
no longer able to bind to the matrix and is eluted directly to allow separa-
tion. The benzamidine column was used to remove thrombin after survivin
histidine-tag cleavage. As thrombin is a serine protease and benzamidine is
a reversible inhibitor of serine proteases, they interacted to allow thrombin
to be separated from the target protein.
Protein purity was analysed by denatured protein electrophoresis (SDS-
PAGE) [88]. The protein concentration was estimated by both the BCA as-
say [89] and absorbance at 280 nm with a spectrophotometer. The extinction
coefficient of each target protein was theoretically calculated using the pro-
tein sequence in ProtParam [90, 91].
2.2 Peptide microarray
Microarray technology is a laboratory tool that provides high-throughput
and rapid information about gene expression or biomolecular interactions.
This technique was developed by Tse Wen Chang in 1983 using antibody
microarrays to identify those cells carrying specific antigens [92–95]. How-
ever, DNA microarray (or DNA chip) technology became more popular af-
ter Davis and Brown published their work in Science in 1995 after studying
Arabidopsis thaliana gene expression [94, 96].
A microarray consists of a solid support (membrane, plastic or glass)
of a few cm2, where biological probes (like DNA, proteins, etc.) are im-
mobilised and exposed to a target molecule or a sample (e.g. a purified
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protein, cDNA, cell lysates, etc.) [97]. The probes and target molecule in-
teraction can be recorded by different methods (e.g. chemoluminescence,
chromogenic enzymatic reactions, radioactive isotopes, etc.) [93, 98], but
the most common one is fluorescent-labelled. The results are quantified
by an image analysis. Nowadays, there is a wide range of microarrays ap-
proaches depending on the employed biological probe (DNA, protein, pep-
tides, chemical compound, tissues, phenotypes, antibodies, etc.) [93].
The peptide microarray technology was introduced by Ronald Frank in
1992. He used spot synthesis microarrays to analyse those antibodies bind-
ing to peptides [99]. This technique allows several thousands of peptides
to be simultaneously screened in a single experiment and different aspects
of protein-protein interactions to be studied. The peptide microarray is also
useful for studying the influence of PTMs on protein interactions, such as
histone studies [100, 101].
In this thesis, the peptide microarray approach (paper III) was used to
discover new interactions with human survivin using PEPperCHIP Peptide
Microarray (PEPperPRINT, GmbH, Heidelberg, Germany) (Figure 2.1). This
technique can be divided into several steps, including microarray prepara-
tion, blocking, pre-staining with the secondary antibody, sample incubation,
staining with secondary antibodies and detection.
The microarray was designed by including the sequences of 19 different
(partial or complete) proteins that are able to interact with survivin. They
were converted into linear peptide segments (15 amino acids long) with a
peptide-peptide overlap of 10 amino acids, and were printed in duplicate in
the microarray.
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Figure 2.1. Microarray sketch
The microarray was synthesised in-situ on a glass support by the PEP-
perPRINT technology, which consists of a laser printer with 24 different
amino acid printing units [102]. The target protein of this experiment was
human recombinant survivin, which presents a 6XHis-tag that was used for
detection. Survivin binding detection was performed by a fluorescent an-
tibody against His-tag (6XHis -Tag Antibody DyLight680). Two types of
positive control peptides were also included as the internal quality con-
trol. 6XHis-tag (HHHHHH) peptides were included to evaluate anti-His
tag antibody binding and to ensure survivin recognition. Human influenza
haemagglutinin (YPYDVPDYAG) peptides were included as a quality con-
trol. These peptides were recognised by the anti-HA antibody.
Firstly, the microarray was incubated with a blocking solution (normally
containing bovine serum albumin) to reduce non-specific binding. Since
secondary antibodies can sometimes interact with synthesised peptides by
giving background interactions, pre-staining with the secondary antibodies
was done to detect and discriminate the signals that did not come from the
interactions. Afterwards, the microarray was incubated with the target pro-
tein (survivin), followed by the secondary antibodies and detection.
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Peptide microarrays have the advantage of being able to screen many
different peptides in a single experiment with a small amount of sample and
are, thus, more stable than protein microarrays. However, some limitations
exist. Peptides are a small fraction of the protein and do not always contain
the full interaction region or the specific secondary structure, which can lead
to false-positive and negative interactions. As they are immobilised in a solid
support, the interaction might also be affected. In addition, binding parame-
ters cannot be obtained from such experiments, and qualitative information
about the interaction is mainly obtained.
This technique is very useful for initially recognising possible interac-
tion partners. However, cross-validations with other techniques that provide
binding information (e.g. MST, ITC, etc.) should also be used.
2.3 MicroScale Thermophoresis
MST is a versatile and sensitive technique for studying biomolecule in-
teractions and estimating their binding affinity. It is based on a physical phe-
nomenon called thermophoresis, described by Carl Ludwig in 1856 [103],
which consists of the directed movement of particles over a temperature gra-
dient. This movement depends on the size, charge and hydration shell of the
studied molecule [104]. An MST measurement consists of heating a sample
inside a thin glass capillary by an infrared laser and recording the move-
ment of molecules by monitoring sample fluorescence [105]. This generates
a microscale temperature gradient (maximum temperature increase of 2-6K)
inside the capillary, which makes the molecules to quickly move away from
the heated spot (depletion). Simultaneously, thermophoresis is followed by
measuring fluorescence at the heated spot. This fluorescence derives from
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a fluorophore that is intrinsic or covalently attached to the molecule of in-
terest. Movement of molecules leads to a concentration change between the
heated spot and the bulk liquid, which can be quantified by the Soret coeffi-
cient (ST ) (Eq. 2.1) of the studied molecule [104, 105].
Chot
Ccold
= e−ST ·(T−T0) (2.1)
where:
Chot = molecule concentration at the localised spot when the laser is on
Ccold = molecule concentration at the localised spot when the laser is off
T = final temperature
T0 = initial temperature
The Soret coefficient is characteristic of the studied molecule and de-
pends on the size, charge and hydration shell of the molecule [105]. When
two molecules interact and form a complex, their size, charge or hydration
shell can be affected. This makes MST a suitable technique for studying
binding formation and obtaining binding affinities. MST measurements can
be divided into different events (initial fluorescence, T-Jump, thermophore-
sis, inverse T-jump and back diffusion), as described in Figure 2.2 [106].
Initial fluorescence is the sample fluorescence before the experiment starts,
done without laser heating. The T-Jump is the fluorescence change that
occurs when the laser is heated up and before the thermophoretic effect
takes place. Thermophoresis is the fluorescence change caused by molecules
moving when the laser is heated up. Inverse T-Jump is the fluorescence
change caused by the sample cooling after turning off the laser.
Back-diffusion is the fluorescence recovery by the mass diffusion of the
molecule after turning off the laser [106].
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Figure 2.2. A. MST optics representation. The IR laser locally heats the sample in-
side capillaries, and sample fluorescence is excited and detected through the same
objective. B. MST traces of a standard binding experiment for different concentra-
tions of the non-labelled protein, including bound and unbound states. Fcold and
Fhot represent the fluorescence region when the IR laser is off and on, respectively.
They are used to calculate the ∆Fnorm utilised for the binding curve calculation. C.
Binding curve. Each point represents the ∆Fnorm of each MST trace for the specific
concentration of the non-labelled protein. [106]
In a binding experiment between two proteins, one of the partners is
fluorescent-labelled, while the other is unlabelled. To estimate their bind-
ing affinity, a serial dilution of the unlabelled protein is mixed with a con-
stant concentration of the labelled protein. The MST traces of each sample
are recorded and binding is analysed by comparing different concentrations.
To obtain good quality binding curves, unlabelled protein titration aims to
maintain the completely bound and unbound states at the higher and lower
concentrations, respectively. In addition, the labelled protein concentration
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should be lower than the expected KD. In thermophoresis, it is also note-
worthy that the initial fluorescence does not vary with the different concen-
trations of the unlabelled protein. The recorded fluorescence is normalised
against the initial fluorescence, Fnorm and used to calculate the normalised
fluorescence difference (∆Fnorm) for each MST trace (Eq. 2.2) [104].
Fnorm =
F
F0
= (1− x)Fnorm(U)+ x ·Fnorm(B) (2.2)
where:
F = fluorescence values after IR laser activation
F0 = fluorescence values prior to laser activation
x = fraction of fluorescence molecules bound to their targets
T0 = initial temperature
Fnorm(U) = contribution of the unbound fluorescence molecule after IR
laser activation
Fnorm(B) = contribution of the complex after IR laser activation
The binding curve can be fitted by plotting the ∆Fnorm against the unla-
belled protein concentrations (on a log10 scale). The dissociation constant
is calculated from the law of mass action described in Eq. 2.3 [107].
x =
c f + c+KD−
√
(c f + c+KD)2−4c f c
2c f
(2.3)
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where:
x = bound fraction of the labelled protein reported by the Fnorm of the
MST measurements
c f = unlabelled protein concentration
c = labelled a protein concentrations
KD = dissociation constant
MST offers several advantages: it is easy to implement, the experiment
can be done in a short time, it does not require large amounts of sample,
there are almost no buffer restrictions, it is immobilisation- and temperature-
free, and there are no molecular weight limitations [108]. However, it is
essential for one of the molecular partners to be fluorescent-labelled, which
can affect the native state of the protein and, therefore, the formation of the
complex.
MST was used to characterise the interaction between the
survivin:borealin and survivin:shugoshin proteins to estimate KD and other
binding parameters. These experiments were performed according to pa-
per III and following the NanoTemper technologies protocol in a Monolith
NT.115 (green/blue) instrument (NanoTemper, Germany) [109]. Survivin
was chemically labelled using the cysteine reactive dye (NT-495-maleimide
and NT-547-maleimide) kit (NanoTemper, Germany). Measurements were
taken using Monolith NT.115 premium capillaries (NanoTemper, Germany).
2.4 Thermal shift assay
The melting temperature (Tm) of a protein is the temperature value at
which half the protein loses its structure and is partially denatured. This in-
formation can be important for the characterisation of a target protein, for
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choosing the optimal buffer for further experiments and for the hit identi-
fication of new drugs [110, 111]. The Tm can also be affected by ligands
binding to the protein [112].
Thermal shift assays (TSA) allow the easy determination of the Tm shift
of a target protein under different conditions (e.g. with different buffers,
ligand binding, etc.) and are normally measured by light scattering or fluo-
rescence techniques [112].
The thermofluor assay is a fluorescent technique developed by Semisot-
nov et al and published in 1991 [113]. These authors studied the bind-
ing of the hydrophobic fluorescent probe, 1-anilino-naphthalene-8-sulfonate
(ANS), to proteins with different structural organisations.
This technique consists of adding a fluorescence dye (sensitive to the en-
vironment) to the protein solution and monitoring protein unfolding when
temperature rises. This is possible because this dye type has a low fluores-
cence signal in polar environments (e.g. an aqueous solution), but presents
a high fluorescence signal when exposed to non-polar environments (e.g. a
denatured protein) (Figure 2.3) [114].
There are several dye types for such assays. In this thesis, SYPRO Or-
ange (Thermo Fisher Scientific. λex 470 nm /λem 570 nm [115]) was used
because it can be easily measured with filters from standard quantitative
PCR instruments [114]. However, sometimes some samples can give un-
clear signals or have a high background, because the dye binds to the native
protein state.
At the beginning of a thermal shift experiment, the protein is in its native
state (folded) and SYPRO Orange presents a low fluorescence signal. How-
ever when temperature rises and the protein starts to unfold, its hydropho-
bic core is exposed to the solution, which allows SYPRO Orange to bind
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it [116]. This increases dye fluorescence until all the molecules are dena-
tured. At the end, the unfolded protein molecules start to aggregate by pro-
ducing dye dissociation and the fluorescence signal starts dropping [117].
From these curves, it is easy to estimate the Tm of the target protein by plot-
ting the first derivative of fluorescence emission according to temperature
(-d(RFU)/dT) [115]. Emission fluorescence is represented in relative fluo-
rescence units (RFU) according to the measured samples and the instrument
used. Figure 2.3 is a sketch of the thermofluor assay.
Figure 2.3. Thermofluor assay. This image shows the lysozyme melting point curve
(black line) and its derivative curve, -d(RFU)/dT (grey dashed line). The minimum
derivative curve point corresponds to the Tm. [117]
A thermofluor experiment was done to analyse the different buffer con-
ditions for human survivin recombinant (Chapter 4). The experiment was
performed in a BioRad CFX96 instrument using a HEX filter (excitation:
515-535 nm, detection: 560-580 nm). The sample was prepared after includ-
ing 2X of SYPRO Orange and 50µM of the protein in the specific buffer.
The protocol consisted of a 30-minute incubation at 20ºC, followed by in-
creasing the temperature by 0.5ºC and a 30-seconds incubation before mea-
suring fluorescence.
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2.5 X-ray Crystallography
To understand how molecules behave, their structure is an important fac-
tor. By knowing their atomic structure, it is possible to better understand
their function and the cellular process where molecules are involved.
Proteins are molecules whose shape and size can vastly differ, approx-
imately 1-10 nm, which makes it impossible to study them by the naked
eye (>100 µm) or with light microscopes (1 mm-100 nm). X-ray crystallog-
raphy is a useful technique for studying the atomic structure of molecules
such as proteins, and there are more than 20 Nobel prizes associated with
this technique (e.g. "The G-protein-couple receptors studies" by Lefkowitz
R.J. or Kobilka B.K. in 2012 [118]).
X-ray (0.01-10 nm) is an electromagnetic (EM) radiation type with a
shorter wavelength than visible (400-700 nm) and ultraviolet (10-400 nm)
light. As atom bond lengths fall within the range of a few Ångströms (e.g. C-
C bond = 1.54 Å), X-ray radiation offers a suitable wavelength for studying
the atomic structure of molecules (0.1 nm = 1Å).
X-ray crystallography consists of irradiating a crystal with an X-ray
beam and collecting the intensities of the relative reflections from the recorded
diffraction patterns. X-ray crystallography requires a crystal to be performed.
A crystal is an ordered three-dimensional array of a specific motif (e.g.
atoms, molecules, proteins, etc.) in a lattice. The motif and lattice form what
is known as the unit cell. The full crystal can be built by translating only the
unit cell into three dimensions. However in the unit cell, there are other
symmetry operators (e.g. inversion, reflection, rotoinversion, glide plane,
rototranslation, translation and rotation). The asymmetric unit is the smallest
portion of a crystal that can generate the unit cell by applying symmetry
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operators. Given macromolecules’ chiral nature, only rotation, translation
and rototranslation can be applied in their crystals, which reduce the number
of possible space groups from 230 to 65 [119, 120].
In a protein crystal, molecules are held together by non-covalent inter-
actions that take place between protein molecules and the solvent, which
makes protein crystals more fragile than small molecule crystals [121].
2.5.1 Crystal formation
Crystal formation can be one of the limitations of protein crystallography
because it depends on many different factors (protein concentration, purity,
temperature, buffer composition, ligands, protein:precipitant ratio, etc.), and
also on the protein’s own specific properties.
The use of crystallisation screening (e.g. sparse matrix screen) allows
different reagents and methods to be evaluated, which provides information
about the conditions leading to crystal formation. The majority of protein
crystals need further optimisation, which can be guided by the “crystalli-
sation phase diagram” (Figure 2.4A). This 2D diagram is a simplification
to help explain how two variables can affect crystal formation. The verti-
cal axis represents the protein concentration, while the horizontal axis rep-
resents the precipitant concentration. Different zones can be described be-
tween these two variables: undersaturated, saturated, metastable or growth,
labile or nucleation and precipitation [122, 123].
The goal is to create a supersaturation solution of the protein and pre-
cipitant, where the protein solution dehydrates in a very controlled manner
to create large enough crystals for single crystal X-ray diffraction. Differ-
ent methods for crystallisation are available, but vapour diffusion is one
of the most widespread [119, 120, 123]. In this method, a small volume of
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protein solution and precipitant solution are mixed together and placed in-
side a closed chamber containing a reservoir with the precipitant solution.
As the precipitant solution in the reservoir has a higher concentration, the
drop slowly dehydrates by vapour diffusion until both the drop and reservoir
reach an equilibrium. In this thesis, hanging and sitting drop vapour diffu-
sion methods were used to obtain lysozyme and survivin crystals. The hang-
ing drop is placed on an inverted cover slip, which also acts as seal at the
top of the reservoir together with oil or vacuum grease. In the sitting drop,
the drop is placed on a pedestal separated from the reservoir [119,120,123].
To crystallise a protein, it is necessary to overcome a similar energy
barrier to a chemical reaction (Figure 2.4B), where the protein molecules
aggregate in an ordered manner to form crystal nuclei. Even though it ap-
pears to be a straightforward process, obtaining well-diffracted crystals is a
trial-and-error process that often proves unsuccessful. So why are crystals
needed?
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Figure 2.4. Phase diagram. A. Crystallisation phase diagram. Under the undersatu-
ration condition, the amount of protein and precipitant is so small that the solution
remains in a single liquid phase (clear drops). The solubility curve consists of the re-
gion where a crystal is in equilibrium with the solution (saturation). The other zones
are considered to be supersaturated zones and differ by the protein:precipitant ra-
tio. Nucleation is a zone where supersaturation is high enough for crystal formation.
The metastable zone is the perfect zone for growing crystals once crystal forma-
tion has started (nucleation). The precipitant zone is where the protein concentra-
tion is too high and produces amorphous precipitation (non-specific or unorganised
aggregation). The arrows represent the crystal formation steps. B. To initialise crys-
tal formation (nucleation), the protein concentration needs to overcome a similar
energy barrier (specific aggregation or organised aggregation) to a chemical reac-
tion. [122, 123]
2.5.2 X-ray diffraction theory
When a protein solution (non-ordered sample) is irradiated by X-rays, it
scatters as waves with different directions and intensities. The total intensity
of a wave in a specific direction consists of the interference of constructive
and destructive waves. This means that the intensity obtained from either a
single molecule or a protein solution is not strong enough to obtain high-
resolution data. However, the scatter signal is amplified when a crystal is ir-
radiated by X-rays. Notwithstanding, many interferences are destructive un-
der specific conditions (when Bragg’s condition is met) and scattering waves
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involve a constructive interference (coherent) by allowing Bragg peaks or re-
flections to be collected. This phenomenon is called diffraction [119, 121].
Bragg’s law and Ewald construction
Bragg’s law (Eq. 2.4) was published by W.H. Bragg and his son L. Bragg
in 1913 [124]. It explains how diffraction occurs. These authors considered
diffraction to be a reflection of X-rays caused by sets of equivalent and par-
allel planes of atoms in a crystal (Figure 2.5). When reflected rays are in
phase (n is integer), a constructive interference of the reflected waves oc-
curs and leads to diffraction [119, 121, 125].
n ·λ = 2 · sinθ (2.4)
where:
d = distance between planes in the lattice.
θ = angle of the incident and scatter X-ray beam.
n = an integer.
λ = the wavelength of X-ray beam.
Each Bragg’s peak (hkl) corresponds to the diffraction from a set of
crystal planes defined by Miller indices, hkl (integers). Its intensity is pro-
portional to the electrons present in that plane. The position of reflections
depends on the crystal lattice (the space group and cell dimension) and their
intensity provides information about the content in the unit cell [119]. The
diffraction pattern of a crystal is a representation of the reciprocal lattice,
which has the same Laue symmetry as the real lattice. By knowing the re-
ciprocal lattice of a crystal, the real lattice can be calculated using Fourier
transform. Ewald’s sphere is a geometrical construction used to explain the
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relation between the reciprocal and the real lattice in crystal diffraction and
is described in Figure 2.5 [121, 125].
Figure 2.5. Left. Representation of the Bragg’s law. Right. Ewald’s sphere construc-
tionIt is a geometric construction with radius 1/λ that relates the real lattice (crystal
planes (hkl), blue) and the reciprocal lattice (green), and theoretically explains the
diffraction of a crystal. This 2D representation represents a set of planes (hkl, blue)
in the real space (crystal) with a plane separation, d. The real lattice origin and the
reciprocal lattice origin are represented by O and O*, respectively. When the crystal
is irradiated by an incident X-ray beam (AO*) with wavelength λ and Bragg´s law
is satisfied, the reflected rays that produced diffraction (OP) will cross the Ewald
sphere at a specific point of the reciprocal lattice, P. The reciprocal vector O*P is
normal to the specific set of planes (hkl) and presents a length of 1/d. By using the
triangle’s properties, Bragg´s law can be extracted from this representation. Crystal
rotation also rotates the reciprocal lattice and allows more reciprocal lattice points to
cross the Ewald sphere. [121]
Each reflection (hkl) is described as the sum of the contributions of all
the scatters (atoms) in the unit cell, and can be computed by the structure
factor equation (Fhkl). The structure factor of a specific reflection (hkl) de-
pends on the electronic properties of the atoms in the unit cell (fj), the am-
plitude of the contribution (hkl) and their position in the unit cell (xj, yj, zj)
(phase) (Eq. 2.5). At a specific position of the unit cell (x,y,z), the electron
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density (ρ(xyz)) can be calculated by the Fourier transform of the structure
factor using Eq. 2.6 [119, 125].
Fhkl =
n
∑
j=1
f je2pii(hx j + ky j + lz j) (2.5)
ρ(x,y,z) =
1
V ∑h ∑k ∑l
|Fhkl|e−2Πi(hx+ky+lz)+iφ(hkl) (2.6)
where:
V = unit cell volume.
|Fhkl| = amplitude of the structure factors.
φ(hkl) = phase.
Phase problem
One of the main difficulties of X-ray diffraction is the phase problem
[119, 121]. During diffraction, the intensities of the reflected waves are col-
lected, but their phases are lost [126]. The phase is essential to determine the
structure factor and, from it, the density map that leads to solve the structure.
Phase provides more important information than what intensity gives to
solve a crystal structure. One good example is the “animal magic” image
published in Kevin Cowtan´s Book of Fourier, where the phases and inten-
sity of two images (one duck and one cat) are mixed and, by inverse Fourier
transform, the resulting images are dominated by the phase used in each
case [119, 126]. The phase problem can be solved by different methods, but
can still sometimes be a challenge.
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In small molecules with a few atoms in the unit cell, direct methods
work well to obtain the phase. Direct methods assume that there are statis-
tical phase relations between certain sets of structure factors and exploit
these relationships to calculate the initial phases [119, 126]. In proteins,
thousands of atoms are often found in the unit cell, which makes these rela-
tions weaker. All this very much complicates the initial phase calculations.
However, such methods are very useful for determining the initial phase
of the marker atom substructure in experimental phasing methods, such as
isomorphous replacement and anomalous dispersion [119, 126].
Patterson method was introduced in 1934 by Arthur Lindo Patterson
and was the first direct method to obtain phase information by using only
experimental information (intensities) [119, 125]. This method consists of
the Patterson function calculation (P(u,v,w)), based on the autocorrelation of
the electron density, which is computed directly from the intensity recorded
by Fourier transform with no phase information (Eq. 2.7). The Patterson
map is built by the maxima of the Patterson function, and contains the inter-
atomic distance vectors between the atoms in the unit cell. The maxima of
the Patterson function are directly proportional to the implied atomic num-
bers, which makes the Patterson map suitable for detecting “heavy” atom
substructures. This map is used as part of other methods to determine heavy
atom positions, in non-crystallography symmetry searches and map averag-
ing, and also in the orientation step of a model search in molecular replace-
ment [119, 127].
P(u,v,w) =
1
V
∞
∑
−∞ hkl
|Fhkl|2 · cos2pi[hu+ kv+ lw] (2.7)
Molecular replacement is one of the commonest methods used to solve
the structure of macromolecules, and it requires a model that is structurally
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related to the target molecule in the crystal [119,127]. This method consists
of placing the atomic model phases from a related known structure in the
unit cell of the unknown structure to be used as initial phases for map re-
construction. The calculation is done in the Patterson space and involves six
dimensional searches over all the possible orientations (rotation) and trans-
lation by considering the intramolecular and intermolecular vectors, respec-
tively. This method is relatively straightforward for solving macromolecule
structure, but has been limited to the macromolecules with structural rel-
atives. Arcimboldo’s approach extends these limits by using small model
fragments like small a-helices or coiled coils to obtain initial phases in pro-
tein structures [128, 129].
2.5.3 Anomalous dispersion
Before explaining how anomalous dispersion techniques work, it is im-
portant to introduce some reflection symmetry concepts.
Reflections can be classified as centric and acentric reflections. Cen-
tric reflections are pairs of reflections that are centrosymmetrically related
through Laue symmetry (space group specific). These special reflections are
found only in centrosymmetrically space groups, their intensity is not af-
fected by anomalous scattering and the phase is restricted. However, acentric
reflections are pairs of reflections that are non-centrosymmetrically related
by Laue symmetry and have no phase restriction [119, 125, 130].
Friedel’s pair is formed between the acentric reflections that are related
by centrosymmetry inversion: F(h,k,l) and F(-h,-k,-l). Their amplitudes are
the same, but phases are opposite. This is described as Friedel´s law. Bijvoet
pairs are acentric reflection pairs generated by applying the point group sym-
metry operator to one of Friedel’s pair mates. Friedel’s pairs are a special
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pair of Bijvoet’s pairs. For example, having the Friedel pair hkl (F+) and
-h-k-l (F-) and applying a 2-fold symmetry operator to Friedel’s mate -h-k-l
(F-), the reflection obtained, h-kl (F-), is Bijvoet´s pair mate of the hkl (F+)
reflection. According to this example, reflection hkl (F+) has two Bijvoet’s
pair mates: –h-k-l (F-) and h-k-l (F-). In addition, the hkl and –h-k-l pair is
called Friedel’s pair [119, 125, 130–132].
Anomalous dispersion techniques (Single/Multi-wavelength Anomalous Dis-
persion; SAD and MAD) are the most widely used methods for de novo
structure determinations [119, 126, 133]. These techniques are based on the
capacity of atoms to absorb X-rays at a certain wavelength (by promoting an
electron transition from a lower energy level to a higher one). The change in
absorption in accordance with the wavelength is called the absorption edge,
and is characteristic of each atom. An atom exhibits anomalous dispersion
when the incident X-ray wavelength comes close to its absorption edge. The
standard atoms present in biomolecules do not contribute to anomalous dis-
persion because their absorption edges are far from the X-ray wavelength
used in X-ray crystallography (apart from S, which can also be used). How-
ever, the presence of heavy atoms in the structure produces anomalous X-ray
dispersion, which is used to solve the phase problem [119, 126].
When an anomalous dispersion effect occurs for certain atoms in the
crystal, the phase and the intensity of Friedel’s pairs shift. Friedel’s law
is broken and the intensity for each mate is no longer equal (Figure 2.6.
Anomalous dispersion methods use this anomalous intensity difference to
localise the scatter atom on the electron density map by direct methods. The
rest of the structure can be determined from this initial phase [119,125,126,
133].
However, different effects can also affect diffraction intensities, which
makes it difficult to discriminate the intensity difference that belongs to the
atom absorption and to obtain accurate phases. Radiation damage is one of
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the commonest effects [119, 125, 126, 133].
The effect of anomalous scattering on a given structure factor behaves
as a complex number composed of two correction terms: a real number (f ’;
dispersive term) and an imaginary number (f”; absorption term) Eq. 2.8.
The dispersive term (f ’) modifies the normal scattering factor (f0), whereas
the absorption term (f”) is 90º advanced in the phase [119, 125, 126].
f = f0+ f ′+ i f ′′ (2.8)
where:
f = anomalous scattering structure factor
f0 = contribution of the normal scattering factor
f ′ and f ′′ = contribution of anomalous scattering factors
Having determined the heavy atom substructure, the calculated ampli-
tude and phase of this contribution can be represented by Harker construc-
tion (Figure 2.6). In a SAD experiment, there are two possibilities for the
phase of each reflection. This phase ambiguity needs to be broken to deter-
mine the structure by using the MAD technique or density modification and
direct methods [119, 126].
Density modification considerably improves initial phases and electron
density maps, which are useful for determining the correct phase from a
SAD experiment. It consists of a group of different techniques that modify
the electron density map according to the common features that a protein
electron density map has such as the fact that it should be possitive. Another
approach is the solvent flattening. A protein crystal contains approximately
half the volume occupied by the ordered protein molecules and the other half
with a solvent. The solvent is disordered and should not present any features
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Figure 2.6. Left. Representation of Friedel pair’s amplitude (|F|) in the absence and
presence of anomalous dispersion. FP, FH and FPH correspond to the structure fac-
tor amplitude of the protein, the scattering atom, and the protein+scattering atom,
respectively. f” is the contribution of anomalous scattering and +/- symbols cor-
respond to the phase direction. Right. Harker construction for a hypothetical SAD
experiment. It illustrates the phase ambiguity of protein structure factor (FPH), even
when the scattering atom substructure (FH) is known [126].
on the electron density map. By bearing this in mind, accurate phases can
be obtained by flattening solvent regions [119, 125, 132, 134].
2.5.4 Data collection
Data collection is one of the most important parts of crystallography ex-
periments and successfully solving the structure depends on it. Protein crys-
tal diffraction data are often collected mainly in large facilities called syn-
chrotrons. Synchrotron science relies on the physical phenomenon of when
a charged particle is accelerated, it emits EM radiation. EM radiation is
produced as electrons pass through a magnetic field. The relativistic speed
of electrons leads to the high flux and brilliance of X-rays because EM
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radiation goes through Lorenz transformation. This is necessary to obtain
good diffraction data in reasonable exposure times, compared to in-house
sources [135].
A synchrotron facility consists of an electron gun, linac (lineal accel-
erator), a booster ring (a small ring where electrons start to be accelerated,
optional), a storage ring (where electrons are accelerated to almost reach
the speed of the light) and beamlines (where X-rays are focused, possibly
monochromatised, and delivered to the experimental hutch). The storage
ring contains bending magnets and insertion devices (wigglers and undula-
tors) that accelerate and direct electrons [121].
Once protein crystals are obtained, they are harvested (“fished”) with
small loops and mounted onto the goniometer to be oriented and exposed
to X-rays. Diffraction collection can be carried out at room temperature,
but cryo-cooling the crystal in liquid nitrogen (approx. 100K) is more com-
monly used to avoid radiation damage (by ionising X-ray radiation).
To be able to solve a crystal structure, all the unique reflections in the
reciprocal lattice must be collected. This can be achieved by rotating the
crystal during collection. The total rotation depends on the symmetry of the
crystal. However, longer exposure times increase radiation damage by creat-
ing disruptions to the crystals lattice, as well as chemical changes that reduce
the intensity and quality of data. Cryo-cooling, including cryo-protectants
(e.g. glycerol, PEG. . . ), cuts exposure times (collecting only minimum an-
gles to ensure that all unique reflections are collected, which depends on
the crystal symmetry) or reduces transmission, which are ways to diminish
damage by radiation [121].
Nowadays, almost all synchrotrons use Single-Photon Counting (SPC)
pixel detectors (e.g. Pilatus or Eiger detectors) for protein crystallography
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collection instead of Charge Coupled Device detectors (CCD) [136]. These
detectors consist in an arrangement of several modules (with Hybrid Photon
Counting Technology) and are characterised by having faster readout times,
single-pixel point-spread functions and good signal-to-noise ratios. They are
useful for fine-slicing data collection and time-resolve experiments.
In paper IV, two data collection types (continuous rotation and inverse-
beam geometry collection) are described and analysed.
2.5.5 Data processing
Data processing involves the following steps: indexing, refining the unit
cell and detector parameters, integration, scaling and merging [119, 137].
Indexing consists of finding the reflection spots of the diffraction pattern
and assigning a consistent set of three integers (or Miller indices) to extend
the reciprocal lattice and determine the crystal symmetry to obtain infor-
mation about cell parameters, the space group and the crystal’s orientation.
The integration step consists of measuring the intensity of each reflection by
considering not only the background signal, but also the crystal and detector
parameters [137].
The data reduction step consists of scaling and merging. Scaling places
all the data (different images, different crystals datasets, etc.) on a common
scale by avoiding experimental variations, such as X-rays intensity, beam
decay, variation in diffracting volume, exposure time and radiation dam-
age. Afterwards, outliers are removed and intensity data, which are obtained
from the different observations made of the same reflection, are averaged.
The unique dataset of the averaged intensities is converted into structure
factor amplitudes [137].
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Different indicators exist to evaluate data quality [137, 138]. Complete-
ness is the percentage of the number of unique reflections recorded versus
the total number of reflections. Rmerge is a traditional internal data consis-
tency measure, which measures the spread of independent reflection inten-
sity measurements. I/sigma represents the ratio between the mean intensity
and its standard error. CC1/2 measures the correlation coefficient between
random half datasets. Redundancy is the ratio of the total number of re-
flections and the number of unique reflections. Anomalous diffraction ex-
periments also include other quality indicators. An anomalous correlation
(Anomalcorr) is the percentage of the correlation between the random half-
sets of anomalous intensity differences. SigAno is the amplitude difference
divided by the error (standard error of the anomalous amplitudes).
Many different programmes can be used for data processing (e.g. Mos-
flm [139], XDS [140], Aimless [138], etc.). In this thesis (paper IV), all
the data processing steps were done using the XDS package (including XS-
CALE and XSCONV) [140].
2.5.6 Model building, refinement and validation
After data processing, it is necessary to determine phases, calculate the
electron density map and build the initial structural model. Reliable struc-
tural models require further model refinement. Refinement consists of mod-
ifying the structural model, to obtain a better agreement between the struc-
ture factors calculated from the model, Fcalc, and the structure factors ob-
served from the experimental data, Fobs [119].
The Fobs-Fcalc map depicts the regions where the model does not agree
with the data. These maps represent positive and negative electron density
areas. The positive electron density indicates that one part of the model is
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missing in that specific area, while the negative electron density indicates
that the model is not correct in that specific area. These map types are very
useful for detecting errors in models. The structural model is built on a
2Fobs-Fcalc map as the model bias is less than on a Fobs map [119].
After each refinement cycle, different parameters are calculated to eval-
uate the progress of refinement. The commonest and most important is R
value (Rwork), calculated using Eq. 2.9 [119, 141].
R =
∑ ||Fobs|− |Fcalc||
∑ |Fobs| (2.9)
According to this formula, the difference between the experimental observa-
tions and the calculated ones (the model) diminishes when Rvalue (Rwork)
also decreases. This is an indication that the model better represents data.
Cross-validation should be included to avoid model bias. This could be
done by calculating the R f ree value, the Rvalue from a small set of data
that was not included during refinement. Another possible validation is the
Ramachandran plot, a 2D plot that shows the regions allowed for amino
acid residues according to dihedral angles ψ and φ of the protein back-
bone [119]. In this thesis, the Phenix package [142] was used to obtain
initial phases (Phaser [143] and Autosol [144] for experimental phasing),
automated building and density modification (Autobuild) [145], refinement
(Refine) [146] and validation (MolProbity) [147]. Coot was also used to
manually build the model in order to improve refinement [148].
2.6 Small Angle X-ray Scattering
Small angle X-ray scattering (SAXS) is a useful technique for obtain-
ing low-resolution structural information of a macromolecule in solution
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[149, 150]. It is often combined with other high-resolution structural deter-
mination methods, such as X-ray crystallography, NMR and electron mi-
croscopy (EM). In addition, this technique is most important for obtaining
structural information about flexible or disorder proteins, which is difficult
to acquire by other techniques [151].
For SAXS measurements, the sample solution (protein solution) is placed
inside a quartz capillary and is irradiated with a collimated monochromatic
X-ray beam (approx. 0.1 nm). Scattered rays are recorded in the detector
by producing a scattering pattern of the sample (Figure 2.7). As the X-ray
diffraction section previously mentions, when a sample solution is irradiated
with an X-ray beam, waves scatter in different directions given the random
orientation of the molecules in solution. This produces an isotropic scatter-
ing pattern that can be recorded and radially averaged. Scattering intensity
(I) is represented according to the module of the momentum transfer,q, (Eq.
2.10), which depends on the scattering angle (2θ ) and beam wavelength
(λ ) [149, 151].
|q|= 4pi
λ
sinθ (2.10)
where:
q = scattering vector
λ = beam wavelength
2θ = scattering angle
The X-ray scattering of a macromolecule in solution depends on the
number of molecules in the specific analysed volume (concentration) and
the excess scattering length density (represented as the contrast) (∆ρ(r)).
SAXS is a contrast technique where the excess scattering length density
comes from the difference between the electron density of the macromolecule
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and the solvent (∆ρ(r) = ρp(r) - ρs). Therefore, a standard SAXS experiment
consists in two measurements: one of the macromolecule (protein) in solu-
tion and another of the solvent (buffer) (Figure 2.7) [150, 151].
Figure 2.7. Schematic illustration of SAXS experiment of molecules in solution
[151].
The excess scattering length density (∆ρ(r)) is related with the scattering
amplitude of particles (A(q)) by Fourier transform (Eq. 2.11) .
A(q) =
∫
∆ρ(r)e(iqr)dr (2.11)
where:
q = scattering vector
r = interactomic distance
V = particle volume
∆ρ(r) = excess scattering length
In an SAXS experiment, what is measured is the scattering intensity,
defined as the product of the amplitude and its complex conjugate averaged
over all the orientations (I(q)=A(q)A(q)*) [150].
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The total scattering intensity recorded equals the form factor of the
molecule (I(q), intramolecular interactions) times the structure factor of so-
lution (S(q), intermolecular interaction, repulsion and attraction);
Itotal(q)=I(q)S(q). The form factor is that which provides information about
the size and shape of the molecule. Therefore, it is the one we are inter-
ested in measuring. To achieve this, one of the requirements of an SAXS
measurement for protein solution is that the sample is monodisperse, and
no intermolecular interactions are present (it allows us to assume that the
structure factor of the solution is 1) [149].
From the scattering curve, different parameters related with the size (at
low q values) and shape of the molecule (at higher q values) can be obtained,
such as the radius of gyration (Rg), particle volume, maximum particle di-
ameter (Dmax) and molecular weight [149, 150].
Rg is the square root mean of the distance of all the electrons from
the particle centre that provides information about the overall molecule size
and, therefore, about its molecular weight and oligomerisation stage. This
parameter can be extracted from the scattering intensity at q=0 using the
Guinier approximation [152]. The Guinier plot is a linear representation
(lnI(q) vs.q2) of the low q region of the scattering curve that allows I(0)
to be obtained. This linear representation also provides information about
the quality and monodispersity of data. Lack of linearity might suggest in-
termolecular interaction (e.g. aggregation) or radiation damage in the sam-
ple [151, 153].
The maximum particle diameter (Dmax) can be obtained from the dis-
tance distribution function (or pr function), which is a histogram of the in-
teratomic vectors within a macromolecule. It can be determined by an indi-
rect Fourier transform of the scattering intensity curve. Rg, I(0) and initial
shape information can be obtained from this function [149, 151].
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The flexibility and folding state of a protein can also be analysed by the
Kratky plot (q2I(q)vs q). where a bell shape curve represents a globular pro-
tein and a plateau curve suggests an extended or unfolded protein [150,151].
In this thesis, SEC-SAXS was used to characterise human survivin in
solution and to compare the results with previously published structure data.
Data were collected at the BM29 beamline [154] of ESRF in France in a
Superdex-75 10/300 GL column. Table 4.1 in Chapter 4 describes the data
collection and data analysis. The ATSAS 2.8.4 package [155] was used to
analyse the scattering curve and obtain structural information. Primus qt
[156] was employed to analyse the scattering curve and estimate the radius
of gyration Rg, Dmax and molecular weight from the Guinier plot and the
distance distribution function p(r).
The DAMMIF [157] and DAMAVER [158] programmes were used to
generate an ab initio shape model from the experimental scattering curve,
which was superimposed to the crystallographic model of survivin. The
CRYSOL [159] software was used to generate a theoretical scattering curve
from the survivin crystallography data to be compared with the experimental
scattering data.
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Bayesian inference
3.1 Background
The origin of statistics dates back to the distant past. There is evidence
that its origins goes back to the Xia Dynasty (2070-1600 BC) in China,
with the first Chinese censuses. Until the 17th century, statistics was almost
descriptive, and a system of data enumeration and organisation. Today, the
use of statistics is much more extensive (from mathematics to social sci-
ences). Statistics can take two different approaches: frequentist (classic) and
Bayesian, depending on the concept of the adopted probability [160]. How-
ever, Bayesian statistics had emerged much earlier than the frequentist type,
which developed much later due to lack of computers. Bayesian statistics
presents complex mathematical problems, which require the use of comput-
ers with a high computation capacity, and also big data software [161, 162].
Statistical inference is the set of statistical techniques that allows us to
draw conclusions about a population, usually from a sample of that popula-
tion.
53
Chapter 3. Bayesian inference
To be able to understand how frequentist and Bayesian inference work,
and their differences, a small journey through the probability theory and
concepts is included.
Probability focuses on assigning numbers to uncertainty, and it has not
only encroached science, but also culture, and the way that society thinks.
Thomas Bayes (1702-1761) was the first person to introduce the Probability
Theory based on previous observations, and established the famous Bayes
Theorem (Eq. 3.1), which was refined and published by Richard Price in
1763 [162–165].
P(A|B) = P(B|A) ·P(A)
P(B)
(3.1)
where:
P(A) = probability of event A occurring.
P(B) = probability of event B occurring.
P(A|B) = conditional probability of event A occurring once event B has
already occurred.
P(B|A) = conditional probability of event B occurring once event A has
already occurred.
This theorem is the basis of Bayesian inference. Frequentist inference,
however, was constructed as an independent science at the beginning of the
20th century, driven by the works of the English-born Karl Pearson and
Ronald A. Fisher [166], and it has been, and still is, widely used [167].
The beginning of the modern Probability Theory lies in the correspon-
dence between two French mathematicians, Blaise Pascal (1623-1662) and
Pierre de Fermat (1601-1665). In 1713, Swiss mathematician Jacob Bernouilli
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established the “Law of large numbers” which states that the relative fre-
quency of an event stabilises around a number after the number of obser-
vations of the event increases. This approximate number is defined as the
frequentist probability of an event occurring. In his book “Théorie analy-
tique des probabilités”, published in 1774, Pierre Simon de Laplace defines
the probability of an event occurring as the ratio of the number of favourable
cases divided by the number of possible cases (when nothing allows us to
expect that one of these cases should occur more than any other; i.e., they are
equally possible). This way to define the probability of an event was used to
develop statistical inference in the 20th century; frequentist inference [167].
The axiomatic definition of probability was established by Russian math-
ematician Andréi Nicoláyevich Kolmogórov (1903-1987) based on the prop-
erties of relative frequencies. From these axioms some probability theorems
have been deduced Figure 3.1, including Bayes Theorem Eq. 3.1 [167].
Figure 3.1. Basic concepts of probability.
Probability and likelihood are two terms that can be confused. Likeli-
hood is not a probability, but is proportional to probability. In fact likelihood
does not obey all probability rules (e.g. likelihoods do not need to add up to
1) [168–170].
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3.2 Frequentist inference
Frequentist statistics calculates the probability of an event occurring, or
not, by the repeated sampling of an experiment, and by taking the limit
of relative frequencies as the probability of the event. For example; if an
experiment is repeated 100 times and 20 of these times fail, the frequentist
probability of failing (P(F)) is 0.2. In frequentist inference, parameter values
are normally unknown and fixed, and data are random. Parameter estimation
is based on choosing the values with the highest likelihood [161, 162, 165,
168, 171].
One of the main inconveniences of frequentist inference consists in need-
ing to have a large number of observations to obtain a good estimation. Un-
fortunately in science, as in other disciplines, this is not always feasible and
can be limited by many factors, such as the amount of sample, time or bud-
get.
3.3 Bayesian inference
Bayesian inference is based on improving the predictions that an event
will occur by adding new information or evidence. It is a statistical ap-
proach used to obtain sharper parameter estimations when the number of
observations is not big enough. In this case, data are fixed and parameters
are unknown random variables whose probability distribution is calculated
by Bayes’ Theorem [161, 162, 168, 171–173].
First of all, the studied parameter (or parameters) should be defined (θ ),
and its/their marginal probability should be calculated including prior be-
liefs (prior probability), without considering experimental data. Secondly,
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the likelihood function of experimental data (D), including the previous be-
liefs of the parameter, should also be quantified. For parameter estimations,
the marginal probability of experimental data should be a proportional con-
stant as data are fixed. The posterior probability can be calculated by com-
bining the prior probability and the data likelihood function using the pro-
portional expression Eq. 3.2 [161, 162, 171, 173].
P(θ |D) ∝ P(D|θ) ·P(θ) (3.2)
where:
P(θ |D) = probability of θ value given the D Posterior distribution.
P(D|θ) = The likelihood of θ given the obtained D. Likelihood function.
P(θ) = marginal probability of θ . Prior probability.
Bayesian inference uses credible regions (CR) instead of confidence in-
tervals (CI) (frequentist inference). CR are calculated from the posterior
density function. Even if CR look very similar to CI, they essentially answer
different things. A 95% CR states that, given the observed data there is a
95% probability that the true parameter value falls inside the credible region.
A 95% CI states that if an experiment is repeated 100 times, approximately
only 5 of the times will the parameter value fall outside the confidence in-
terval as the experiments are all done in the same way [161, 162, 173, 174].
This approach has been used in papers I, III and IV to estimate different
parameters that enhance the merging step of X-ray crystallographic data
reduction (paper I/IV), which better estimate the binding curve and binding
kinetics parameters from the MST binding assays (paper III).
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In paper I, the multivariate Bayesian approach is used to estimate the
structure factor amplitudes of a pair of observations from a specific reflec-
tion, and to calculate their differences (from synthetic data). This approach
can have a major impact on the data analysis of the experimental phasing for
X-ray crystallography (paper IV) or on the pump-probe diffraction exper-
iments, where the calculation of accurate amplitude differences is essential
for further analyses. In conclusion, with paper I multivariate analyses pro-
vide a better structure factor amplitude difference estimation than univariate
analyses, which can strongly influence the results, as shown in paper IV.
Figure 3.2 describes the multivariate Bayesian approach used in papers I
and IV.
Figure 3.2. The multivariate Bayesian approach for structure-factor amplitude es-
timations (paper I). I and F represent the structure factors’ amplitude and intensity,
respectively. LKJ is the (Lewandowski, Kurowicka and Joe) log-likelihood correla-
tion [175]. MCMC is the Markov chain Monte Carlo method.
In paper IV, the multivariate Bayesian approach, described in paper
I, is applied to estimate the anomalous difference in the experimental SAD
data, (collected from lysozyme and survivin crystals), and is compared with
the commonly used univariate approach. According to these results (paper
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IV), a multivariate approach enhances experimental phasing. With survivin,
this was essential to obtain initial phases and to solve the structure. More-
over, two different data collection methods (continuous rotation and inverse-
beam geometry) were tested. According to the results, better phases were
obtained by the continuous rotation method. However, as the data quality of
continuous rotation was also slightly better that the inverse-beam geometry,
it was not possible to accept that one method was better than the other.
In paper III, the multivariate Bayesian inference is used to estimate
the parameters of the binding curves obtained from the collected MST data
in the survivin interactions (with borealin and shugoshin proteins), and to
compare this method with the standard non-linear least square (NLLSQ)
regression method [176]. The NLLSQ method analysis consists of a single
point binding estimation curve which, according to the paper III results, ap-
pears to be considerably influenced by the outliers present in the data. The
multivariate Bayesian inference approach represents the binding estimate
curve as a multitude of curves corresponding to the joint posterior probabil-
ity distribution calculated for each studied parameter. This approach showed
a weaker impact by data outliers, which led to a better estimation of the bind-
ing curve and, therefore, of the binding kinetic parameters (e.g. KD). Figure
3.3 shows a diagram of the multivariate Bayesian approach used in paper
III to estimate the KD of the binding.
In these papers, the power of Bayesian inference for obtaining a better
estimation of the collected data was probed. However, it is important to
be aware of the main pitfalls of Bayesian inference: prior distribution. As
previously described, Bayesian inference relies on the prior beliefs of the
studied parameter value to obtain a better parameter estimation from the
collected data. If prior distribution is too conservative, experimental data
can be censored and affect the posterior distribution calculation.
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Figure 3.3. Multivariate Bayesian approach for KD estimation (paper III). KD,
bound (B) and unbound (U) fluorescence, concentration of the fluorescent-labelled
protein (c f l) and the unlabelled protein concentration (c) are kinetic parameters.
They are all random variables, except for the unlabelled protein concentration (c)
that is constant. λ and ν are the parameters for the Student-T distribution, the de-
grees of freedom and scale parameter, respectively, and are also variable. MCMC is
the Markov chain Monte Carlo method
Summary
The Bayesian inference approach was applied for the data analyses in
papers I, III and IV. The main goal of using this approach is to obtain bet-
ter parameter estimations from the collected data and to compare these re-
sults with previous analysis methods. This chapter includes an introduction
to statistical inference, followed by a comparison made between Bayesian
inference and frequentist inference, and the different approaches used in pa-
pers I, III and IV.
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Survivin interactions
Human survivin is the protein of interest in this work. In paper III, the
interactions between survivin and human shugoshin proteins, hSgol1 and
hSgol2, was analysed. Recombinant human survivin was overexpressed in
E.coli, and the purified protein was characterised before the interaction and
structural studies (paper III). This chapter focuses on the characterisation
of human survivin protein and protein-protein interactions studies that led
to the publication of paper III.
4.1 Human survivin production and characterization
4.1.1 Survivin production
Survivin was overexpressed in the E.coli BL21 star (DE3) strain using a
modified pET28a vector (pHIS8) containing kanamycin selection and eight
histidine tags (to facilitate protein purification), followed by a thrombin
cleavage site (LVPR’GS) and the full sequence of the human survivin gene
(BIRC5). This construct (vector) was obtained from Verdecia’s lab [22] and
was used for the protein expression of survivin for papers III and IV.
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To obtain large amounts of protein, survivin expression was optimised
on a small scale by varying the temperature (30ºC and 37ºC), IPTG con-
centrations (0.5, 0.75 and 1 mM) and induction times (2 h, 4 h and 6 h).
High expression levels are not the only important fact in protein production
optimisation, but protein solubility is also valuable. The protein expression
level and solubility were analysed by SDS-PAGE electrophoresis by com-
paring the induced and non-induced samples, and the soluble (supernatant)
and insoluble (pellet) fractions after cell disruption. Although all the tested
conditions showed part of the protein in the insoluble fraction (inclusion
bodies), the induction performed at 30ºC for 4 h also led to large amounts
of soluble survivin protein (paper III).
Survivin production was performed according to the protocol published
in paper III, including some of the improvements described below. Expres-
sion increased by the addition of 80 µM ZnCl2 to the media before induc-
tion. Since survivin contains a zinc-binding site in the BIR domain, it is not
surprising that the addition of zinc to media helps protein folding and leads
to a bigger amount of soluble protein. Survivin was purified in two steps:
affinity chromatography and SEC (paper III). Nickel affinity purification
was ameliorated by including 20 mM imidazole in the binding buffer (50
mM Tris, pH 8, 500 mM NaCl and 20 mM imidazole), two washing steps
at low imidazole concentrations before eluting (30 mM and 40 mM) and a
final elution gradient (40 mM to 250 mM). In addition, overnight dialysis
in SEC buffer (50 mM, 150 mM NaCl and 1 mM DTT) was an essential
step for protein stability as the protein precipitated when exposed to high
concentrations of imidazole over an extended period.
The presence of small tags in proteins (e.g. His-tag) does not usually
interfere with their characterisation. However, as His-tags are commonly
disorder regions, tag removal can improve crystal formation and packing
(ordered structure), which leads to better diffraction and higher resolution
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crystals. For crystallisation purposes (paper IV), the His-tag was cleaved
off from survivin by incubating at 10-12ºC overnight with the thrombin pro-
tease (GE Healthcare). After cleavage, thrombin was removed by binding it
to a HiTrap Benzamidine FF column (GE Healthcare) (Chapter 2). Crystal
quality was also improved by adding an extra SEC purification as a final
step.
Figure 4.1. Survivin purification profiles and SDS-PAGE gel..Left. The IMAC sur-
vivin profile where 100% buffer B corresponds to 500 mM Imidazole. Right. The
SEC survivin profile. The SDS-gel shows samples from the IMAC and the SEC
purification. The IMAC wells correspond to the initial diluted sample, the diluted
non-specific binding sample (0-100 ml) and the elution peak (approx. 160-200 ml),
respectively.
Figure 4.1 provides examples of survivin purification and sample purity.
According to these results, high-purity survivin samples can be obtained
after nickel purification. However, the SEC step allows the elimination of
small contaminants and more homogenous protein sample can be obtained
Figure 4.1.
4.1.2 Buffer screening
Protein stability is an important factor for protein studies and may be
strongly linked to the buffer conditions. A thermofluor assay (Chapter2) was
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used to test different buffer conditions and to monitor the melting tempera-
ture (Tm) shift of survivin. Thirteen of the commonest buffers used in protein
purification and crystallisation were selected and tested (Figure 4.2) [177].
These buffers cover a wide range of pH values as protein charge and sta-
bility are closed related to pH. Sodium chloride (NaCl) and dithiothreitol
(DTT) were also added to increase the ionic strength of the buffer and to
avoid damage by oxidation, respectively.
Figure 4.2. Survivin buffer screening results using a thermofluor assay. A. Repre-
sentation of the first derivative of fluorescence emission (–d(RFU)/dT) in accordance
with temperature, which was calculated from the initial melting curves using the Bio-
Rad CXF software. B. Temperature melting of survivin in specific buffers. Buffers 1,
2 and 11 were not included as no proper information was obtained from the curves.
The analysed buffers were: sodium citrate pH 5.0 (buffer 1), sodium acetate pH 4.5
(buffer 2), MES pH 6.5 (buffer 3), potassium phosphate pH 6.0 (buffer 4), sodium
phosphate pH 7.5 (buffer 5), HEPES pH 7.5 (buffer 6), MOPS pH 7.0 (buffer 7),
ammonium acetate pH 7.3 (buffer 8), Tris pH 8.0 (buffer 9), Tricine pH 8.0 (buffer
10), Bis-Tris propane pH 8.5 (buffer 11), PIPES pH 7.0 (buffer 12), Glycine pH 9.0
(buffer 13). All the buffers were prepared at a final concentration of 100 mM, in-
cluding 150 mM NaCl and 1 mM DTT. Each condition was replicated 3 times and
the results gave the average.
In line with these results, basic pH values (over 7) gave a higher Tms than
acidic pH values (below than 7), which suggests that protein stability would
also be greater at a basic pH. Four of the tested buffers can be considered the
most recommended ones, including sodium phosphate pH 7.5, glycine pH 9,
Tricine pH 8 and Tris pH 8. As there are no large differences in the survivin
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Tm among these buffers, and as Tris buffer has been used satisfactorily with
survivin in previous studies, further experiments were done in 50 mM Tris-
HCl pH 8, 150 mM NaCl and 1 mM DTT. Phosphate buffer was not chosen
because the initial purifications trial did not succeed with it.
4.1.3 Survivin: dimer in solution
Previous crystallography and NMR publications have described survivin
as a homodimer, but the function of the protein in this oligomer state is still
not fully clear [22–24]. Survivin homodimer has been previously related
with anti-apoptosis function at the cytoplasm because it is well-known that
during cell division, survivin acts as a monomer by forming part of the CPC
in the nucleus. In this thesis, the size exclusion chromatography (Figure
4.1) and small angle X-ray scattering (Figure 4.3) results were combined to
determine sample quality, and the size and oligomer stage of the survivin
protein used in our experiments (papers III and IV).
The SEC result shows a homogenous peak around 40 kDa, which sug-
gests that the survivin sample is a dimer (a theoretical monomer value of
18.74 kDa) and there was no obvious aggregation in the sample. These re-
sults were also confirmed by the SAXS analysis, as summarised in Table 4.1.
The Guinier plot did not show any sample aggregation, and the obtained Rg
and Dmax values were characteristic of small proteins. Molecular weight was
also estimated to be approximately 33 kDa. The Kratky plot showed partial
flexibility in the protein (Figure 4.3C), which could be associated with the
linker between the BIR domain and the C-terminal.
The comparison made of the experimental and theoretical scattering
curves (calculated from a crystallography model, PDB id 1F3H [22]) gave
a χ2 value that came closer to 1 (χ2 = 0.93). This result indicates a good
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agreement between the protein crystal structure model and the protein in
solution (Figure 4.3D). This was also represented by superposing the crys-
tal structure with the ab initio model shape calculated from the scattering
curve.
Figure 4.3. SAXS analysis of survivin A. Scattering curve (logI vs q(Å−1)). B. Dis-
tance distrubution function (pr function). C Kratky plot (Iq2 vs q(Å−1)). D Compari-
son of the experimental scattering data (red) and the calculated scattering curve from
the crystal structure PBD id:1F3H (green) [22]. Superposition of the 1F3H structure
(blue) [22] into the ab initio envelop (grey) calculated from the SAXS data.
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Table 4.1. SAXS results of survivin.
Data collection parameters
Beamline BM29, ESRF, Grenoble, France
Wavelength (Å) 0.99
q range (nm−1) 0.025-5
Injected sample (mg) ≈3
SEC column Superdex 75 100/300GL
Temperature (K) 283.15
Structural parameters
I(0) (cm−1)[from Guinier] 8.05 ± 0.02
Rg (Å)[from Guinier] 28.7 ± 0.2
I(0) (cm−1)[p(r) function] 8.10 ± 0.03
Rg (Å)[p(r) function] 29.5 ± 0.3
Dmax(Å) 95
Porod volume estimate, Vp (Å3) 56040
Molecular weight(MW) determination
MW [from Porod volume (Vp/1.6)] (kDa) 35.02
MW (kDa) – Bayesian inference primus [178] 33.10 (31.30-34.95)
Modelling parameters
Shape reconstruction DaMMIF [157]
Symmetry P2
No. of models averaged/total 20
DAMAVER NSD (var) [158] 1.26± 0.14
Software employed
Data evaluation Primus qt, GNOM [156]
Computation of model intensities CRYSOL [159]
3D graphics representations UCSF Chimera [25]
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4.2 Microarray peptide analysis
Paper III describes two new interaction partners of the human survivin
protein, hSgol1 and hSgol2, which belong to the shugoshin-like protein fam-
ily. These interactions were established by using shugoshin peptides and the
specific sequence was determined by the microarray experiments described
in paper III. In this microarray, the amino acid sequence of 19 different
human proteins (complete or partial) (Table 4.2) was analysed in small 15
residue-long peptides with an overlap of 10 residues (paper III). There were
three main reasons for selecting these proteins:
1. They are involved in similar cellular processes, such as survivin, cell
division and programmed cell death
2. Previous studies have already shown interactions with survivin, which
can be used as positive controls
3. They present similar amino acid sequences to proteins, which have
already been known to interact with survivin
Table 4.2 summarises the different analysed proteins and their characteris-
tics to be selected. The amino acid sequences of some were not fully stud-
ied, and only a few residues were included in the analysis. The truncated
sequences are represented in the table by the number of residues included in
the analysis, next to the protein name. The microarray results indicated two
basic peptides as the principal interaction candidates. These two peptides
correspond to the C-terminal region of the shugoshin-like protein family
(hSgol1 and hSgol2) and were used to design the peptides for the MST anal-
ysis (paperIII). In addition, other peptides with weaker intensities were also
selected for further analyses, such as borealin (paper III), BCL2, JADE-3
and BCL6.
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Table 4.2. Proteins for the microarray peptide analysis.
Protein name Characteristics/Function
p53 Involved in apoptosis and cell division
BCL-2 Involved in apoptosis
BCL-6 Involved in apoptosis
Aurora kinase A Involved in chromosomal instability
Aurora kinase B A CPC member
Smac/DIABLO1−134 Involved in apoptosis (+ control)
Borealin1−93 A CPC member (+ control)
Histone H3 Involved in the chromatin structure (+ control)
JADE-3105−173 Sequence similarity with INCEPT interaction region
FLJ44060 isoform CRA_b268−514 High sequence similarity with the borealin interaction region
LysM3143−204 High sequence similarity with the borealin interaction region
hSgol1 Involved in cell division and previously studied
hSgol2 Involved in cell division and is hSgol1-related
Tubulin y Involved in cell division (microtubules)
Tubulin a Involved in cell division (microtubules)
Tubulin b Involved in cell division (microtubules)
Anx13A intestine94−149 Sequence similarity with the INCEPT interaction region
Anx13102−141 Sequence similarity with the INCEPT interaction region
SYCP2L582−628 Sequence similarity with the INCEPT interaction region
Even though many of these proteins do not show any interaction with
survivin in the microarray assay, possible interactions taking place under
other conditions cannot be ruled out. This technique analyses protein inter-
actions using the small peptides attached to a surface. This means that any
interaction requiring a protein secondary/tertiary structure, or is affected by
the immobilisation of the peptide, is not reported. Some specific interactions
can also depend on PTM in the proteins and are not reported either.
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4.3 Borealin interaction with survivin
The borealin and survivin interaction has been previously studied as part
of the CPC. In paper III, we chose borealin6−20 (GSSRVAKTNSLRRRK)
as a positive control of the interaction with survivin. This short peptide, in-
cluding part of N-terminal borealin (residues 6-20), was selected from the
microarray analysis and sufficed to weakly interact with survivin. It pre-
sented a 10.8 µM KD (paper III). Previous studies have reported that the
main interaction between these two proteins included borealin20−78 and the
survivin region that followed the BIR domain and the first part of the C-
terminal (homodimerisation region). However, no dissociation constant in-
formation has been reported.
The survivin and borealin6−20 interaction can be involved to increase the
stability of the previously described complex. The CPC structural studies
have shown that the borealin6−20 region is located at the end of the survivin
C-terminal (Figure 4.4). However, only a few residues (LRRRK) from the
borealin peptide have been modelled in these structures and are located at
the end of the survivin C-terminal (139-141). This suggests that the rest of
the peptide (6-14) can be folded around the survivin C-terminal.
4.4 Shugoshin and survivin interactions
4.4.1 Microscale Thermophoresis
The new interactions between hSgol1291−312/ hSgol21066−1085 and sur-
vivin were validated by the MST experiments (paper III), which reported
dissociation constants valued at 80.7 and 1.6 µM, respectively.
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Figure 4.4. The borealin and survivin crystal structure, PDB id 2QFA [30]. Survivin
is shown in blue and borealin in grey and pink. The pink part of the helix shows the
five last residues of the peptide used in the MST experiments (borealin6−20).
Previous studies have shown that survivin can interact with proteins
by presenting an N-terminal that mimics the phosphorylated N-terminal of
histone H3 (Ala1-Arg2-Thr3ph-Lys4). hSgol1 presents such an N-terminal
region (Ala1-Lys2-Glu3-Arg4), and its interaction with survivin and with
the CPC has been previously reported. The new interaction between
hSgol1291−312 and survivin (paper III) was more than 100 residues far from
the previous hSgol1 N-terminal interaction, which suggests that this new in-
teraction does not necessarily interfere with the previous one. On the con-
trary, hSgol2 does not have such an N-terminal, and no direct interaction
with survivin has been previously reported. However, both shugoshin pro-
teins have been required for the centromeric localisation of the CPC during
cell division via the direct interaction with other CPC members. This sce-
nario suggests that this new interaction with survivin might also be involved
in the shugoshin:CPC complex.
The multiple sequence alignment of the shugoshin proteins C-terminal
region from different mammalian species (paper III) showed that the pep-
tide region was highly conserved between them, which could indicate its
usefulness for some of their functions.
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Peptides hSgol1291−312 and hSgol21066−1085 are highly positive-charged
and their secondary structure was predicted as coiled coil and α-helix, re-
spectively. However, the results of the circular dichroism described in pa-
per III revealed that their structure looked more like a random coil, and that
hSgol1291−312 presented a more local order than hSgol21066−1085.
4.4.2 Survivin-eGFP and hSgol1195−312 interaction using FSEC
To improve our knowledge about the survivin and hSgol1 protein inter-
action, a longer peptide that included the previous peptide was designed,
cloned and overexpressed, namely hSgol1195−312. This region was selected
by using the PHD secondary structure predictor tool [179] and the RADAR
tool [180], which detected the repeating regions inside the protein sequence.
The aim of this design was to extend the small peptide (hSgol1291−312), in-
cluding a specific secondary structure (coiled coils) and possible repetitive
regions in the protein sequence. As this new hSgol1 peptide, hSgol1195−312,
has the molecular weight of a small protein (approx. 14 kDa), the complex
formation between survivin and hSgol1195−312 was preliminarily analysed
using SEC.
When two proteins interact and form a complex, the molecular weight
of this complex should be larger than the individual proteins, and elutes
earlier from SEC by being able to easily analyse possible complex for-
mation. As absorbance at 280 nm is common for almost all proteins, en-
hancer green fluorescence protein (eGFP, λex 485 nm /λem 512 nm [80]) was
fused to survivin to monitor the complex elution by fluorescence size exclu-
sion chromatography (FSEC) by an FP-2020 Plus fluorescence detector. By
considering that fluorescence is more sensitive than absorbance at 280 nm,
FSEC permits small amounts of labelled protein (survivin-eGFP) to be used
for detection. This has the advantage of the amount of unlabelled protein
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(hSgol1195−312) being several times bigger to ensure full complex formation
(survivin-eGFP:hSgol1195−312). Proteins survivin-eGFP and hSgol1195−312
were expressed and purified by standard methods, and the specific protocols
are described in Appendix B.
The complex formation was analysed by incubating survivin-eGFP (2.5
µM) and hSgol1195−312 (68 µM) for 1 h at 12ºC, injecting them into the
FSEC and eluting at 0.4 ml/min in 50 mM Tris, pH 7.5, 300 mM NaCl and
1 mM DTT. Similar experiments were run with the individual proteins and
a negative control using eGFP (2.5 µM) instead of survivin-eGFP. To esti-
mate the molecular weight of the complex and the other proteins, previous
calibrations using a Gel Filtration Calibration Kit (GE Healthcare) under the
same buffer conditions were also done.
Earlier survivin-eGFP elution in the presence of hSgol1195−312 was ob-
served, which suggests complex formation (Figure 4.5A). Survivin-eGFP is
the heaviest component of the complex with a theoretical MW of 46 kDa (vs.
14.7 kDa for hSgol1195−312). According to the Superdex 200 calibration ex-
periment (Figure 4.5E), survivin-eGFP eluted later than what its theoretical
MW suggested (an apparent MW of 33 kDa). hSgol1195−312 eluted at a vol-
ume corresponding to a protein with an MW of 32 kDa, which suggests that
hSgol1195−312 is in a dimeric form (Figure 4.5C). The simplest explanation
for the apparent MW of the complex formed between survivin-eGFP and
hSgol1195−312 (49 kDa) is 1:1 stoichiometry. This faster elution was not ob-
served in the negative control gel filtration experiment using eGFP (30kDa;
the apparent MW in gel filtration was 26.5 kDa) and hSgol1195−312 (Figure
4.5B). However, this interaction needs to be confirmed by other methods,
such as MST.
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Figure 4.5. FSEC experiment results. A. Chromatography of the survivin-eGFP
construct alone (black) and co-injected with hSgol1195−312 (red). B. Negative con-
trol. Chromatography of the eGFP construct alone (black) and co-injected with
hSgol1195−312 (yellow dashed line). C. hSgol1195−312 chromatogram. D. SDS –
PAGE of the studied proteins. The numbers on the left correspond to the differ-
ent molecular weights (kDa) of the protein ladder. The numbers at the top rep-
resent the different loaded samples; 1. eGFP (30kDa), 3. survivin-eGFP (46kDa),
3. survivin (16.4kDa), 4. hSgol1195−312 (14.7kDa), 5. Trx-tag afterhSgol1195−312
cleavage (15.9kDa). E. Superdex200 Increase 10/300GL calibration using the fol-
lowed mixture of different proteins: ferritin (440kDa), aldolase (158kDa), conal-
bumin (75kDa), ovalbumin (44kDa), carbonic anhydrase (29kDa), ribonuclease A
(13.7kDa), aprotinin (6.5kDa). They are labelled from 1 to 7, respectively.
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4.5 Co-crystallisation trials of survivin and shugoshin
peptides.
One important factor of studying protein-protein interactions is to know
the specific region where the interaction occurs. This provides functional in-
formation that helps to better understand the cellular pathways where these
proteins are involved. Cell division requires the interaction of many different
proteins at the same time (e.g. the CPC formation), which makes it difficult
to fully understand how it works. By knowing that survivin and shugoshin
proteins interact, many other questions appear, such as how does this inter-
action occur? Do shugoshin proteins bind to the dimeric or the monomeric
form of survivin? Can shugoshin bind survivin when it interacts with the
CPC? Some of these questions can be answered by studying the atomic
structure of the complex.
The co-crystallisation of survivin and hSgol1291−312 and hSgol21066−1085
was tested by the sitting drop vapour diffusion approach and commercial
crystallisation screens (e.g. PACT, Morpheus, etc.). The drops containing
the complex solution (1 mM survivin + 5 mM shugoshin peptides, respec-
tively) and the precipitant solution at a ratio of 1:1, were set up using a
mosquito crystallisation robot on MRC2 plates. Plates were incubated at
20ºC for 1-3 weeks.
Crystals with different shapes and sizes were found under several con-
ditions (Figure 4.6). Some of the conditions presented crystals that differed
in size and shape in the presence of hSgol1291−312 or hSgol21066−1085, re-
spectively, which could indicate complex formation. These crystals were
harvested, cryo-cooled and tested in ESRF. A few of them diffracted to high
resolution (e.g. 2.5Å), but no peptide was found in the structure.
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Figure 4.6. Crystals obtained from the co-crystallisation of Survivin and shugoshin
peptides.A and B show the crystals from the condition 0.2 M Potassium sodium
tartrate tetrahydrate 20% w/v PEG 3350 (PACT premier – Mol dimension), including
peptides hSgol1 and hSgol2, respectively. C and D show crystals from the condition
D3 0.1 M Potassium chloride 0.1 M Sodium HEPES 7.0 15% w/v PEG 5000 MME
(Proplex – Mol. dimension), including peptides hSgol1 and hSgol2, respectively.
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4.6 Survivin isoforms
The expression of survivin isoforms has been related to several diseases,
and some studies have suggested that the formation of heterodimers with
survivin can play an important role towards survivin regulation. However,
no information is available about their structure, function or how they can
interact with survivin. In this thesis, preliminary expression and purifica-
tion studies have been done in the survivin-2B and survivin-∆Ex3 isoforms
in order to obtain pure and stable proteins for structural and interactional
studies.
Four different constructs were designed and tested for the expression
of survivin isoforms. They included different localisations of the his-tag
(pET28b+8xHis and pET29b) and two different protein fusion tags (pET48b
and pET49b) to increase protein solubility. The survivin-2B and survivin-
∆Ex3 genes were obtained from Mahotka’s lab [56] in the pET29b vector,
and the other constructs were generated using the InFusion HD Cloning
kit. Two different E.coli strains were used to analyse the expression: One
Shot BL21 Star (DE3) and RossettaT M (DE3) pLysS. This last one was
selected to improve the expression of the eukaryotic proteins in E.coli. A
small-scale test expression was performed according to the pET manual
protocol [82]. Figure 4.7 summarises the best expression results for each
construct in RossettaT M (DE3) pLysS .
Survivin-2B overexpression was significantly better than survivin-∆Ex3.
However, the majority of the protein formed inclusion bodies. Survivin-
2B expression gave small fractions of soluble protein using pET29b and
pET28b+8His. Survivin-∆Ex3 was almost not expressed in any construct or
strain, which suggests that either it may be toxic for cells or codon optimi-
sation is needed. Survivin-2B purification using the his-tag construct was
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not successful because the protein was unstable and did not bind properly to
nickel affinity column. The survivin-2B fusion to TRX (pET48b) gave good
purified protein yields, but survivin-2B was unstable after cleavage of the
TRX.
Summary
The microarray peptide technology allowed us to easily identify some
Figure 4.7. The test expression of survivin isoforms in different pET vectors
(pET29b, pET28b, pET48b and pET49b). The top and bottom gels correspond to
survivin-2B and survivin-∆Ex3, respectively. The different samples are described
by; N: non-induced, I: induced, S: supernatant and P: pellet or inclusion bodies.
The red arrow marks the position where the survivin isoform expression is expected.
The molecular marker corresponds to the PageRuler Plus Prestained Protein Ladder
(Thermo Fisher Scientific).
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possible interaction partners for survivin. Microscale thermophoresis was
used to evaluate these interactions, which led to two novel interactions be-
tween survivin and the shugoshin family, as published in paper III. Recom-
binant survivin isoforms appeared less stable than survivin, which suggests
that testing codon optimisation or other expression systems may be neces-
sary.
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Concluding remarks
The work presented in this thesis focuses on the discovery of new interac-
tion partners of the human survivin protein to improve our understanding of
its function and its involvement in different diseases. This work also shows
the strength of Bayesian inference in data analyses by focusing on crystal-
lography data and binding affinity calculations.
Paper I demonstrates how the multivariate Bayesian model yields more
precise structure factor amplitude estimates from pairs of recorded diffrac-
tion intensities than the common univariate model. Structure factor ampli-
tude difference calculations play an important role in solving experimen-
tal problems or for evaluating time-dependent structural changes in pump-
probe experiments. Therefore, a better estimation can improve these analy-
ses.
Paper II provides a detailed review of current knowledge about the non-
malignant properties of survivin and focuses on its implication to autoim-
mune diseases. Survivin has been reported to be a promising biomarker and
a therapeutic target in autoimmune diseases. In clinical applications, sur-
vivin measurements have been shown to be important for diagnostic and
therapeutic treatments.
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Paper III reports two novel interactions between human survivin and
the shugoshin-like protein family. These interactions provide information to
help us better understand how survivin or the CPC complex is localised at
the inner centromere during cell division. As shugoshin proteins protect the
cohesion of sister chromatids (cohesin complex) during cell division, the
interaction with survivin at the centromere can also play a role in the re-
moval of centromeric cohesin before chromosomal segregation. Paper III
also demonstrates how the Bayesian inference analysis can greatly improve
the calculation of binding curves and the dissociation constant estimation.
This approach is less sensitive to the presence of data outliers than standard
non-linear least square (NLLSQ) regression methods and provides an inde-
pendent binding data analysis without involving any manual intervention,
which helps avoid any human subjective bias.
Paper IV confirms that the multivariate Bayesian model described in
paper I very much improves the anomalous difference calculations that are
essential for SAD experimental phasing in difficult cases (e.g. survivin). It
also suggests that as long as the X-ray beam flux is attenuated at a rea-
sonable level, radiation damage does not apparently influence the chosen
data collection approach (continuous rotation and inverse-beam geometry)
and the results. An alternative pairing method that employs the multivariate
Bayesian model concluded that pairing closer Bijvoet’s reflections presents
a much lower correlation than pairing Friedel’s reflections, having an effect
in the anomalous difference estimation.
Future view
The rapid development of high computational capacity machines have
allowed the complex mathematical problems that Bayesian inference ex-
hibits to be solved. Bayesian inference is a powerful technique that helps
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obtain more precise estimations and improved data analysis. However, the
time spent on these calculations is still one of the main limitations. Tech-
nology improvements may lead to implement Bayesian inference into more
standard data analysis procedures.
Why is it relevant to continue studying survivin at the molecular level?
Survivin is involved in quite a few severe diseases, such as autoimmune dis-
ease and cancer. Cancer is one of the main causes of global death where sur-
vivin has been related with more critical cancer stages. Studies conducted at
the molecular level reveal important information about the protein function
and specific interaction regions with other proteins. Elucidating new inter-
actions can lead to a better understanding of cell division and apoptosis, and
to an improvement in diagnosing or treating related diseases.
Why is it important to obtain more robust knowledge about survivin iso-
forms?
These isoforms have been related with different disease stages, but there is
still a world to be discovered at the molecular level. As they have been sug-
gested to regulate and interact with survivin, elucidating their structure and
how these interactions take place will also be important to fully understand
the survivin function.
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Appendix A
Survivin gene
ATGGGTGCCCCGACGTTGCCCCCTGCCTGGCAGCCCTTTCTC
AAGGACCACCGCATCTCTACATTCAAGAACTGGCCCTTCTTGGA
GGGCTGCGCCTGCACCCCGGAGCGGATGGCCGAGGCTGGCTTC
ATCCACTGCCCCACTGAGAACGAGCCAGACTTGGCCCAGTGTTT
CTTCTGCTTCAAGGAGCTGGAAGGCTGGGAGCCAGATGACGAC
CCCATAGAGGAACATAAAAAGCATTCGTCCGGTTGCGCTTTCCT
TTCTGTCAAGAAGCAGTTTGAAGAATTAACCCTTGGTGAATTTT
TGAAACTGGACAGAGAAAGAGCCAAGAACAAAATTGCAAAGG
AAACCAACAATAAGAAGAAAGAATTTGAGGAAACTGCGAAGA
AAGTGCGCCGTGCCATCGAGCAGCTGGCTGCCATGGATTGA
hSgol1195−312 gene
CTGAAAAAACATTGTAATAGCATCTGCCAGTTCGATAGCCT
GGATGATTTTGAAACCAGCCATCTGGCAGGTAAAAGCTTTGAAT
TTGAACGTGTTGGTTTTCTGGATCCGCTGGTTAACATGCATATTC
CGGAAAATGTTCAGCATAATGCATGCCAGTGGTCAAAAGATCA
GGTTAATCTGAGCCCGAAACTGATTCAGCCTGGCACCTTTACCA
AAACCAAAGAAGATATTCTGGAAAGCAAAAGCGAACAGACCA
AAAGCAAACAGCGTGATACCCAAGAACGTAAACGTGAAGAGA
AACGTAAAGCCAATCGTCGTAAAAGTAAACGTATGAGCAAATA
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CAAAGAGAAC
Survivin-2B gene
ATGGGTGCCCCGACGTTGCCCCCTGCCTGGCAGCCCTTTCTC
AAGGACCACCGCATCTCTACATTCAAGAACTGGCCCTTCTTGGA
GGGCTGCGCCTGCACCCCGGAGCGGATGGCCGAGGCTGGCTTC
ATCCACTGCCCCACTGAGAACGAGCCAGACTTGGCCCAGTGTTT
CTTCTGCTTCAAGGAGCTGGAAGGCTGGGAGCCAGATGACGAC
CCCATTGGGCCGGGCACGGTGGCTTACGCCTGTAATACCAGCAC
TTTGGGAGGCCGAGGCGGGCGGATCACGAGAGAGGAACATAAA
AAGCATTCGTCCGGTTGCGCTTTCCTTTCTGTCAAGAAGCAGTTT
GAAGAATTAACCCTTGGTGAATTTTTGAAACTGGACAGAGAAA
GAGCCAAGAACAAAATTGCAAAGGAAACCAACAATAAGAAGA
AAGAATTTGAGGAAACTGCGAAGAAAGTGCGCCGTGCCATCGA
GCAGCTGGCTGCCAaTGGATTGA
Survivin-∆Ex3 gene
ATGGGTGCCCCGACGTTGCCCCCTGCCTGGCAGCCCTTTCTC
AAGGACCACCGCATCTCTACATTCAAGAACTGGCCCTTCTTGGA
GGGCTGCGCCTGCACCCCGGAGCGGATGGCCGAGGCTGGCTTC
ATCCACTGCCCCACTGAGAACGAGCCAGACTTGGCCCAGTGTTT
CTTCTGCTTCAAGGAGCTGGAAGGCTGGGAGCCAGATGACGAC
CCCATGCAAAGGAAACCAACAATAAGAAGAAAGAATTTGAGGA
AACTGCGAAGAAAGTGCGCCGTGCCATCGAGCAGCTGGCTGCC
ATGGATTGAGGCCTCTGGCCGGAGCTGCCTGGTCCCAGAGTGGC
TGCACCACTTCCAGGGTTTATTCCCTGGTGCCACCAGCCTTCCTG
TGGGCCCCTTAGCAATGTCTTGA
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Table A.1. Primers used
Primer sequences (5’ to 3’)
pWarf-survivin Forward
AAGAAGGAGACTCGAGATGGGTGCCCCGACG
pWarf-survivin Reverse
CAGCTGGCTGCCATGGATGGATCCTTGGAAGTCT
pET48b hSgol1195−312 Forward
CGGGTACCAGGATCCTCTGAAAAAACATTGTAATAGCATCTGC
pET48b hSgol1195−312 Reverse
TGCGGCCGCAAGCTTAGTTCTCTTTGTATTTGCTCATACGT
pET28+8His survivin-2B Forward
CGCGCGGCAGCCATATGATGGGTGCCCCGACGTTG
pET28+8His survivin-2B Reverse
GCTCGAATTCGGATCCTCAATCCATGGCAGCCAGCTG
pET48b survivin-2B Forward
CGGGTACCAGGATCCGATGGGTGCCCCGACGTT
pET48b survivin-2B Reverse
TGCGGCCGCAAGCTTTCAATCCATGGCAGCCAGCT
pET49b survivin-2B Forward
CGGGTACCAGGATCCGATGGGTGCCCCGACGTT
pET49b survivin-2B Reverse
TGCGGCCGCAAGCTTTCAATCCATGGCAGCCAGCT
pET28+8His survivin-∆Ex3 Forward
CGCGCGGCAGCCATATGATGGGTGCCCCGACGTTG
pET28+8His survivin-∆Ex3 Reverse
TGTGGGCCCCTTAGCAATGTCTTAGGGATCCGAATTCGAG
pET48b survivin-∆Ex3 Forward
CGGGTACCAGGATCCGATGGGTGCCCCGACGTT
pET48b survivin-∆Ex3 Reverse
TGCGGCCGCAAGCTTCAAGACATTGCTAAGGGGCCCA
pET49b survivin-∆Ex3 Forward
CGGGTACCAGGATCCGATGGGTGCCCCGACGTT
pET49b survivin-∆Ex3 Reverse
TGCGGCCGCAAGCTTCAAGACATTGCTAAGGGGCCCA
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hSgol1195−312 production
The hSgol1195−312 sequence was cloned into a pET48+ vector and the
peptide was expressed in E.coli BL21 star (DE3) strain cells. This construct
contains kanamycin selection and the thioredoxin (TRX) protein sequence,
followed by a 6-histidine tag, the HRV3C cleavage site (LEVLFQ’GP) and
the hSgol11195−312 sequence. hSgol1195−312-TRX was overexpressed at 180
rpm and 30ºC with 0.5 mM IPTG for 3-4 h. Cells were harvested and lysed
by the standard method described in Chapter 2. This peptide was purified
in three steps: nickel affinity chromatography, reverse chromatography and
SEC. Affinity chromatography was performed by binding the protein to the
column with 50 mM Tris, pH 8, 300 mM NaCl buffer and by eluting the
protein in two steps using the same buffer that contained imidazole (10 mM
step, and a gradient step from 10 mM to 200 mM). After affinity purifica-
tion, the TRX-6His tag was cleaved by overnight dialysis (dialysis buffer:
50 mM Tris, pH7.5, 300 mM NaCl and 14 mM β6-mercaptoethanol) with
HRV3C protease (1:100). TRX was removed by reverse his-tag purification,
followed by a SEC step in a Superdex 75 100/300 GL column (SEC buffer:
50 mM Tris, pH 7.5, 300 mM NaCl, 5 mM DTT buffer). The purified pro-
tein was analysed by SDS-PAGE electrophoresis and protein concentration
was estimated by absorbance at 280 nm.
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Survivin-eGFP production
The survivin gene was cloned into the pWarf(-) vector and the protein
was overexpressed in E.coli Lemo21 (DE3) strain cells. This construct con-
tains kanamycin selection and the full human survivin protein sequence,
followed by the HRV3C protease cleavage site, the eGFP gene and a C-
terminal 8xHis-tag. Expression was optimised at 180 rpm and 25ºC with
different concentrations of IPTG (0 mM, 0.1 mM, 0.2 mM and 0.4 mM) and
of L-rhamnose (0 mM, 0.10 mM, 0.25 mM, 0.50 mM, 0.75 M and 1 mM).
Twenty-four different conditions were tested. The protein expression level
was analysed by measuring the relative fluorescence (RFU) in the complete
cells and normalising the results with the optical density (OD600) of each
culture (Figure B.1).
Figure B.1. This histogram represents the survivin-eGFP expression test results.
The x-axis depicts the different tested L-rhamnose concentrations, while the y-axis
is the relative fluorescence normalised by the OD600 of each culture. Each series
represents the different tested IPTG concentrations.
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According to these results (FigureB.1), survivin-eGFP was higher ex-
pressed with 0.1mM L-Rhamnose and 0.1 mM IPTG concentrations. Big-
scale expression was performed in LB media containing 50 ug/ml Kan, 34
µg/ml chloramphenicol (Cam) 80 µM ZnCl2 and 0.1 mM L-Rhamnose. In-
duction was started at OD600nm 0.4-0.6 with 0.1 mM IPTG. Cells were
incubated at 180 rpm and 25ºC overnight.
Survivin-eGFP was purified by the same protocol described for survivin
in paper III, but a Superdex-200 10/300 GL column was used. Apart from
the standard protein detection at 280 nm, eGFP fluorescence was also mon-
itored during elution.
An eGFP construct was also generated from the pWarf(-) vector to ex-
press the eGFP protein for the negative control. The protein was expressed
in the E.coli BL21 star (DE3) strain and purified according paper III pro-
tocol .
91

Acknowledgements
It feels like it was only yesterday when I was walking along the Lund-
berg lab corridor for the first time. However, almost 5 years since that day
have gone by. The journey has been great, but also hard, and it would not
have been possible without the support of many people who I wish to thank.
First of all, I would like to thank you, Gergely, for giving me the chance
of joining your group and introducing me to the crystallography world. Your
knowledge is endless and I am glad to have been able to learn it from you.
Thank you for all the questions that led me away from my comfort zone, and
made me think and learn. If I have to pick up something from all these years,
it would be the beamtimes. They have been exhausting but also great fun and
inspiring. I will never forget the fateful beamtime when it took us forever to
arrive at the ESRF and we got 1.7Å of what we thought was survivin-2B.
Maria B., for being my co-supervisor and for all the inspiring and en-
joyable survivin discussions, which I really enjoyed.
To my examiner, Richard, for guiding and helping me over the years
and for giving me the chance to participate in an XFEL beamtime with his
group. It was a great experience.
To all the members of Katona´s group as it has been a pleasure to work
with you all. Annette, for being so kind to me and for showing me around
my first months in the lab. Ida, for all the fun in the THz beamtimes. Viktor,
I really enjoyed the Oviedo conference. Good luck, you are the next! Hassan
and Stan, it was fantastic having you in the group. Sofia, Nauras, Nathalie,
Maja and Torbjorn, thank you all for working as bachelor/master students
93
Appendix B.
with me and bringing cheeriness to the survivin’s project. Maja, for being
my travel partner in the survivin project in the last years, for all your help
and your huge support in the hardest times. We had a lot of fun!
To all the people who form part of the Lundberg lab; Neutze´s group
(Rebecka, Rob B, Petra B, Cecilia W., Greger, Per, Giorgia, Daniel,
etc.), Westenhoff´s group (Sebastian, Elin C., Leo, Andrea, Amke,
Linnéa, Joachim, Matthijs, Weixiao, Leticia, Michal, Ann, Laras, etc.),
Brändén´s group (Gisela, Cecilia S., Andreas, Swagatha, Jonatan, etc.),
Höög´s group (Johanna, Davide, Jake, Dimitra, etc.), Hedfalk´s group
(Kristina, Florian, Jessica, etc.), Burmann’s group (Bjorn,Darius, Emi-
lie, Laura, Josh, Lisa, Damasus, Ashis, Irena, Ylber, etc.); thank you all
for the good times, fika times and beer clubs! I feel really glad to have met
you all.
Rebecka thanks for all the laughs and good times. I am looking for-
ward to being your neighbour in Bollelingsås. Leo, my dancing partner and
a great friend! Thanks for all your positivity and support. Petra B., for all
the teaching moments and dances during the thesis parties. The chocolate
really helped me on these long days. Tina, Per and Giorgia, without whom
I couldn’t imagine a work trip being so fun as it was in Japan. Thank you for
the amazing experience. I think it is time to be a unicorn again! Weixiao, I
really appreciate you having been so patient and supporting me in the dif-
ficult times. I really enjoyed discussing science with you and learning from
you. Elin C., I really enjoyed having you around and the funny Tällberg.
Cecilia S., thank you for being so sweet with me. El Campello is waiting
for us! Florian, for all the laughs and fun. I am looking forward to the next
opera. Davide, it was awesome to have you as roomie! Kristina and Gisela,
it was such a wonderful experience teaching and learning in your courses.
To all people who are no longer in the Lundberg lab, but have also
94
Appendix B.
formed part of this journey; thank you for all the fun (Elin D., Rhawnie,
Rob D., David, Mike, Stefan, Stephan, Rob D. (I love your Halloween par-
ties), Petra E., Oskar, Rajiv (another Australia?), Alex, Rosie, Parveen,
Nasha, Rachel, Jenni, Jenny, Emil, Ash, Amit, etc.). Rosie, for making
crystallography so much fun!; for all your help and positivity. Nasha and
Rachel, for all the good times in the moon and the crazy lyase experience!
Parveen, thank you for all your help when I was a newbie in the lab and for
the afterworks.
I thank all the collaborators and co-authors who made this possible, es-
pecially Christian and Malin.
Lars, Bruno and Valida, the lab would not work without you!
To my family, especially my parents, Fernando and María José. There
are no words for saying thank you to you. You have been the best teachers
that I could have, and your hard work and perseverance have been my in-
spiration. To my big brother Fer, for taking care of me and supporting me.
Thanks for always making me smile.
To all my friends in Sweden and back at home. Belén, Maryam and
Mario, for taking care of me for all these years and never letting me fall.
Cosme, Moi, Sandra and Usua, those unconditional friends who have al-
ways been there, for both good and bad. To the “Biologuillos group”, be-
cause my journey in science started with you, and the genetic exercises! I
am so pleased to have such good friends.
Simón, thank you for being at my side throughout this long journey and
making it funnier. For your support and help in the hardest times. For all
the times that you have picked me up late from the lab and listened to me
talking about science and my crazy experiments. For helping me feel calm
when I did not feel it, and for not running away. I love you.
95
Appendix B.
96
Bibliography
[1] G. M. Cooper, The Cell: A Molecular Approach. Sunderland (MA): Sinauer Associates, 2nd ed.,
2000.
[2] B. Alberts, A. Johnson, J. Lewis, et, and al, Biology of the Cell. New York: Garland Science,
4th ed., 2002.
[3] B. Pucci, M. Kasten, and A. Giordano, “Cell cycle and apoptosis,” Neoplasia, vol. 2, no. 4,
pp. 291–9, 2000.
[4] Q. L. Deveraux and J. C. Reed, “IAP family proteins–suppressors of apoptosis,” Genes Dev,
vol. 13, no. 3, pp. 239–52, 1999.
[5] G. Gravina, C. Wasen, M. J. Garcia-Bonete, M. Turkkila, M. C. Erlandsson, S. Toyra Silfver-
sward, M. Brisslert, R. Pullerits, K. M. Andersson, G. Katona, and M. I. Bokarewa, “Survivin in
autoimmune diseases,” Autoimmun Rev, vol. 16, no. 8, pp. 845–855, 2017.
[6] H. Doolittle, A. Morel, and D. Talbot, “Survivin-directed Anticancer Therapies – A Review of
Pre-clinical Data and Early-phase Clinical Trials,” European Oncology, vol. 6, no. 1, pp. 10–14,
2010.
[7] G. Duan and D. Walther, “The roles of post-translational modifications in the context of protein
interaction networks,” PLoS Comput Biol, vol. 11, no. 2, p. e1004049, 2015.
[8] J. P. Hughes, S. Rees, S. B. Kalindjian, and K. L. Philpott, “Principles of early drug discovery,”
Br J Pharmacol, vol. 162, no. 6, pp. 1239–49, 2011.
[9] P. L. Kastritis and A. M. Bonvin, “On the binding affinity of macromolecular interactions: daring
to ask why proteins interact,” J R Soc Interface, vol. 10, no. 79, p. 20120835, 2013.
[10] D. Vasudevan and H. D. Ryoo, “Regulation of Cell Death by IAPs and Their Antagonists,” Curr
Top Dev Biol, vol. 114, pp. 185–208, 2015.
[11] J. Silke and P. Meier, “Inhibitor of apoptosis (IAP) proteins-modulators of cell death and inflam-
mation,” Cold Spring Harb Perspect Biol, vol. 5, no. 2, 2013.
97
BIBLIOGRAPHY
[12] G. Wu, J. Chai, T. L. Suber, J. W. Wu, C. Du, X. Wang, and Y. Shi, “Structural basis of IAP
recognition by Smac/DIABLO,” Nature, vol. 408, no. 6815, pp. 1008–12, 2000.
[13] D. Finlay, P. Teriete, M. Vamos, N. D. P. Cosford, and K. Vuori, “Inducing death in tumor cells:
roles of the inhibitor of apoptosis proteins,” F1000Res, vol. 6, p. 587, 2017.
[14] B. Yan, “Research progress on Livin protein: an inhibitor of apoptosis,” Mol Cell Biochem,
vol. 357, no. 1-2, pp. 39–45, 2011.
[15] P. Obexer and M. J. Ausserlechner, “X-linked inhibitor of apoptosis protein - a critical death
resistance regulator and therapeutic target for personalized cancer therapy,” Front Oncol, vol. 4,
p. 197, 2014.
[16] A. Marchler-Bauer and S. H. Bryant, “CD-Search: protein domain annotations on the fly,” Nu-
cleic Acids Res, vol. 32, no. Web Server issue, pp. W327–31, 2004.
[17] G. Ambrosini, C. Adida, and D. C. Altieri, “A novel anti-apoptosis gene, survivin, expressed in
cancer and lymphoma,” Nat Med, vol. 3, no. 8, pp. 917–21, 1997.
[18] D. C. Altieri, “Survivin - The inconvenient IAP,” Semin Cell Dev Biol, vol. 39, pp. 91–6, 2015.
[19] N. K. Sah, Z. Khan, G. J. Khan, and P. S. Bisen, “Structural, functional and therapeutic biology
of survivin,” Cancer Lett, vol. 244, no. 2, pp. 164–71, 2006.
[20] S. Mokuda, T. Miyazaki, Y. Ito, S. Yamasaki, H. Inoue, Y. Guo, W. S. Kong, M. Kanno, K. Taka-
sugi, E. Sugiyama, and J. Masumoto, “The proto-oncogene survivin splice variant 2B is induced
by PDGF and leads to cell proliferation in rheumatoid arthritis fibroblast-like synoviocytes,” Sci
Rep, vol. 5, p. 9795, 2015.
[21] E. C. LaCasse, S. Baird, R. G. Korneluk, and A. E. MacKenzie, “The inhibitors of apoptosis
(IAPs) and their emerging role in cancer,” Oncogene, vol. 17, no. 25, pp. 3247–59, 1998.
[22] M. A. Verdecia, H. Huang, E. Dutil, D. A. Kaiser, T. Hunter, and J. P. Noel, “Structure of the
human anti-apoptotic protein survivin reveals a dimeric arrangement,” Nat Struct Biol, vol. 7,
no. 7, pp. 602–8, 2000.
[23] L. Chantalat, D. A. Skoufias, J. P. Kleman, B. Jung, O. Dideberg, and R. L. Margolis, “Crys-
tal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical
extensions,” Mol Cell, vol. 6, no. 1, pp. 183–9, 2000.
[24] C. Sun, D. Nettesheim, Z. Liu, and E. T. Olejniczak, “Solution structure of human survivin and
its binding interface with Smac/Diablo,” Biochemistry, vol. 44, no. 1, pp. 11–7, 2005.
[25] E. F. Pettersen, T. D. Goddard, C. C. Huang, G. S. Couch, D. M. Greenblatt, E. C. Meng, and
T. E. Ferrin, “UCSF Chimera–a visualization system for exploratory research and analysis,” J
Comput Chem, vol. 25, no. 13, pp. 1605–12, 2004.
98
BIBLIOGRAPHY
[26] D. C. Altieri, “Survivin and IAP proteins in cell-death mechanisms,” Biochem J, vol. 430, no. 2,
pp. 199–205, 2010.
[27] K. M. Andersson, M. Turkkila, M. C. Erlandsson, A. Bossios, S. T. Silfversward, D. Hu, L. Ek-
erljung, C. Malmhall, H. L. Weiner, B. Lundback, and M. I. Bokarewa, “Survivin controls bio-
genesis of microRNA in smokers: A link to pathogenesis of rheumatoid arthritis,” Biochim Bio-
phys Acta Mol Basis Dis, vol. 1863, no. 3, pp. 663–673, 2017.
[28] D. Trnski, M. Gregoric, S. Levanat, P. Ozretic, N. Rincic, T. M. Vidakovic, D. Kalafatic, I. Mau-
rac, S. Oreskovic, M. Sabol, and V. Musani, “Regulation of Survivin Isoform Expression by GLI
Proteins in Ovarian Cancer,” Cells, vol. 8, no. 2, 2019.
[29] C. M. O’Connor and J. U. Adams, Essentials of Cell Biology. Cambridge, MA: NPG Education,
2010.
[30] A. A. Jeyaprakash, U. R. Klein, D. Lindner, J. Ebert, E. A. Nigg, and E. Conti, “Structure of a
Survivin-Borealin-INCENP core complex reveals how chromosomal passengers travel together,”
Cell, vol. 131, no. 2, pp. 271–85, 2007.
[31] S. Ruchaud, M. Carmena, and W. C. Earnshaw, “The chromosomal passenger complex: one for
all and all for one,” Cell, vol. 131, no. 2, pp. 230–1, 2007.
[32] M. Carmena, M. Wheelock, H. Funabiki, and W. C. Earnshaw, “The chromosomal passenger
complex (CPC): from easy rider to the godfather of mitosis,” Nat Rev Mol Cell Biol, vol. 13,
no. 12, pp. 789–803, 2012.
[33] M. S. van der Waal, R. C. Hengeveld, A. van der Horst, and S. M. Lens, “Cell division control
by the Chromosomal Passenger Complex,” Exp Cell Res, vol. 318, no. 12, pp. 1407–20, 2012.
[34] S. Hindriksen, S. M. A. Lens, and M. A. Hadders, “The Ins and Outs of Aurora B Inner Cen-
tromere Localization,” Front Cell Dev Biol, vol. 5, p. 112, 2017.
[35] E. Niedzialkowska, F. Wang, P. J. Porebski, W. Minor, J. M. Higgins, and P. T. Stukenberg,
“Molecular basis for phosphospecific recognition of histone H3 tails by Survivin paralogues at
inner centromeres,” Mol Biol Cell, vol. 23, no. 8, pp. 1457–66, 2012.
[36] J. Du, A. E. Kelly, H. Funabiki, and D. J. Patel, “Structural basis for recognition of H3T3ph and
Smac/DIABLO N-terminal peptides by human Survivin,” Structure, vol. 20, no. 1, pp. 185–95,
2012.
[37] A. E. Kelly, C. Ghenoiu, J. Z. Xue, C. Zierhut, H. Kimura, and H. Funabiki, “Survivin reads
phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B,” Science, vol. 330,
no. 6001, pp. 235–9, 2010.
[38] D. Clift and A. L. Marston, “The role of shugoshin in meiotic chromosome segregation,” Cyto-
genet Genome Res, vol. 133, no. 2-4, pp. 234–42, 2011.
99
BIBLIOGRAPHY
[39] S. A. Kawashima, Y. Yamagishi, T. Honda, K. Ishiguro, and Y. Watanabe, “Phosphorylation of
H2A by Bub1 prevents chromosomal instability through localizing shugoshin,” Science, vol. 327,
no. 5962, pp. 172–7, 2010.
[40] S. A. Kawashima, T. Tsukahara, M. Langegger, S. Hauf, T. S. Kitajima, and Y. Watanabe,
“Shugoshin enables tension-generating attachment of kinetochores by loading Aurora to cen-
tromeres,” Genes Dev, vol. 21, no. 4, pp. 420–35, 2007.
[41] Y. Yamagishi, T. Honda, Y. Tanno, and Y. Watanabe, “Two histone marks establish the inner
centromere and chromosome bi-orientation,” Science, vol. 330, no. 6001, pp. 239–43, 2010.
[42] A. A. Jeyaprakash, C. Basquin, U. Jayachandran, and E. Conti, “Structural basis for the recog-
nition of phosphorylated histone h3 by the survivin subunit of the chromosomal passenger com-
plex,” Structure, vol. 19, no. 11, pp. 1625–34, 2011.
[43] T. Tsukahara, Y. Tanno, and Y. Watanabe, “Phosphorylation of the CPC by Cdk1 promotes chro-
mosome bi-orientation,” Nature, vol. 467, no. 7316, pp. 719–23, 2010.
[44] A. P. Baron, C. von Schubert, F. Cubizolles, G. Siemeister, M. Hitchcock, A. Mengel, J. Schroder,
A. Fernandez-Montalvan, F. von Nussbaum, D. Mumberg, and E. A. Nigg, “Probing the catalytic
functions of Bub1 kinase using the small molecule inhibitors BAY-320 and BAY-524,” Elife,
vol. 5, 2016.
[45] H. Okada and T. W. Mak, “Pathways of apoptotic and non-apoptotic death in tumour cells,” Nat
Rev Cancer, vol. 4, no. 8, pp. 592–603, 2004.
[46] D. R. McIlwain, T. Berger, and T. W. Mak, “Caspase functions in cell death and disease,” Cold
Spring Harb Perspect Biol, vol. 5, no. 4, p. a008656, 2013.
[47] S. Fulda and D. Vucic, “Targeting IAP proteins for therapeutic intervention in cancer,” Nat Rev
Drug Discov, vol. 11, no. 2, pp. 109–24, 2012.
[48] Z. Song, X. Yao, and M. Wu, “Direct interaction between survivin and Smac/DIABLO is es-
sential for the anti-apoptotic activity of survivin during taxol-induced apoptosis,” J Biol Chem,
vol. 278, no. 25, pp. 23130–40, 2003.
[49] N. K. Sah and C. Seniya, “Survivin splice variants and their diagnostic significance,” Tumour
Biol, vol. 36, no. 9, pp. 6623–31, 2015.
[50] B. Ryan, N. O’Donovan, B. Browne, C. O’Shea, J. Crown, A. D. Hill, E. McDermott,
N. O’Higgins, and M. J. Duffy, “Expression of survivin and its splice variants survivin-2B and
survivin-DeltaEx3 in breast cancer,” Br J Cancer, vol. 92, no. 1, pp. 120–4, 2005.
[51] A. Pavlidou, C. Kroupis, and K. Dimas, “Association of survivin splice variants with prognosis
and treatment of breast cancer,” World J Clin Oncol, vol. 5, no. 5, pp. 883–94, 2014.
100
BIBLIOGRAPHY
[52] J. Gaytan-Cervantes, C. Gonzalez-Torres, V. Maldonado, C. Zampedri, G. Ceballos-Cancino, and
J. Melendez-Zajgla, “Protein Sam68 regulates the alternative splicing of survivin DEx3,” J Biol
Chem, vol. 292, no. 33, pp. 13745–13757, 2017.
[53] A. G. Antonacopoulou, K. Floratou, V. Bravou, A. Kottorou, F. I. Dimitrakopoulos, S. Marousi,
M. Stavropoulos, A. K. Koutras, C. D. Scopa, and H. P. Kalofonos, “The survivin -31 snp in
human colorectal cancer correlates with survivin splice variant expression and improved overall
survival,” Anal Cell Pathol (Amst), vol. 33, no. 5, pp. 177–89, 2010.
[54] M. J. Duffy, N. O’Donovan, D. J. Brennan, W. M. Gallagher, and B. M. Ryan, “Survivin: a
promising tumor biomarker,” Cancer Lett, vol. 249, no. 1, pp. 49–60, 2007.
[55] M. E. Johnson and E. W. Howerth, “Survivin: a bifunctional inhibitor of apoptosis protein,” Vet
Pathol, vol. 41, no. 6, pp. 599–607, 2004.
[56] C. Mahotka, J. Liebmann, M. Wenzel, C. V. Suschek, M. Schmitt, H. E. Gabbert, and C. D.
Gerharz, “Differential subcellular localization of functionally divergent survivin splice variants,”
Cell Death Differ, vol. 9, no. 12, pp. 1334–42, 2002.
[57] A. Pavlidou, M. Dalamaga, C. Kroupis, G. Konstantoudakis, M. Belimezi, G. Athanasas, and
K. Dimas, “Survivin isoforms and clinicopathological characteristics in colorectal adenocarcino-
mas using real-time qPCR,” World J Gastroenterol, vol. 17, no. 12, pp. 1614–21, 2011.
[58] S. De Maria, G. Pannone, P. Bufo, A. Santoro, R. Serpico, S. Metafora, C. Rubini, D. Pasquali,
S. M. Papagerakis, S. Staibano, G. De Rosa, E. Farina, M. Emanuelli, A. Santarelli, M. A. Marig-
gio, L. Lo Russo, and L. Lo Muzio, “Survivin gene-expression and splicing isoforms in oral
squamous cell carcinoma,” J Cancer Res Clin Oncol, vol. 135, no. 1, pp. 107–16, 2009.
[59] H. Caldas, L. E. Honsey, and R. A. Altura, “Survivin 2alpha: a novel Survivin splice variant
expressed in human malignancies,” Mol Cancer, vol. 4, no. 1, p. 11, 2005.
[60] S. Cory and J. M. Adams, “The Bcl2 family: regulators of the cellular life-or-death switch,” Nat
Rev Cancer, vol. 2, no. 9, pp. 647–56, 2002.
[61] J. Waligorska-Stachura, N. Sawicka-Gutaj, M. Zabel, W. Liebert, P. Gut, A. Czarnywojtek, and
M. Ruchala, “Decreased expression of survivin 2B in human pituitary adenomas. A preliminary
study,” Folia Histochem Cytobiol, vol. 55, no. 1, pp. 21–25, 2017.
[62] M. H. Malcles, H. W. Wang, A. Koumi, Y. H. Tsai, M. Yu, A. Godfrey, and C. Boshoff, “Char-
acterisation of the anti-apoptotic function of survivin-DeltaEx3 during TNFalpha-mediated cell
death,” Br J Cancer, vol. 96, no. 11, pp. 1659–66, 2007.
[63] E. A. Noton, R. Colnaghi, S. Tate, C. Starck, A. Carvalho, P. Ko Ferrigno, and S. P. Wheatley,
“Molecular analysis of survivin isoforms: evidence that alternatively spliced variants do not play
a role in mitosis,” J Biol Chem, vol. 281, no. 2, pp. 1286–95, 2006.
101
BIBLIOGRAPHY
[64] M. Espinosa, G. Ceballos-Cancino, R. Callaghan, V. Maldonado, N. Patino, V. Ruiz, and
J. Melendez-Zajgla, “Survivin isoform Delta Ex3 regulates tumor spheroid formation,” Cancer
Lett, vol. 318, no. 1, pp. 61–7, 2012.
[65] G. Georgiou and P. Valax, “Expression of correctly folded proteins in Escherichia coli,” Current
Opinion in Biotechnology, vol. 7, no. 2, pp. 190–197, 1996.
[66] R. Vincentelli, A. Cimino, A. Geerlof, A. Kubo, Y. Satou, and C. Cambillau, “High-throughput
protein expression screening and purification in Escherichia coli,” Methods, vol. 55, no. 1,
pp. 65–72, 2011.
[67] G. L. Rosano and E. A. Ceccarelli, “Recombinant protein expression in Escherichia coli: ad-
vances and challenges,” Frontiers in microbiology, vol. 5, pp. 172–172, 2014.
[68] F. A. Marston, “The purification of eukaryotic polypeptides synthesized in Escherichia coli,” The
Biochemical journal, vol. 240, no. 1, pp. 1–12, 1986.
[69] I. Iost, J. Guillerez, and M. Dreyfus, “Bacteriophage T7 RNA polymerase travels far ahead of
ribosomes in vivo,” Journal of bacteriology, vol. 174, no. 2, pp. 619–622, 1992.
[70] F. W. Studier and B. A. Moffatt, “Use of bacteriophage T7 RNA polymerase to direct selective
high-level expression of cloned genes,” Journal of Molecular Biology, vol. 189, no. 1, pp. 113–
130, 1986.
[71] H. Jeong, V. Barbe, C. H. Lee, D. Vallenet, D. S. Yu, S.-H. Choi, A. Couloux, S.-W. Lee, S. H.
Yoon, L. Cattolico, C.-G. Hur, H.-S. Park, B. Ségurens, S. C. Kim, T. K. Oh, R. E. Lenski, F. W.
Studier, P. Daegelen, and J. F. Kim, “Genome Sequences of Escherichia coli B strains REL606
and BL21(DE3),” Journal of Molecular Biology, vol. 394, no. 4, pp. 644–652, 2009.
[72] S. Wagner, M. M. Klepsch, S. Schlegel, A. Appel, R. Draheim, M. Tarry, M. Högbom, K. J. van
Wijk, D. J. Slotboom, J. O. Persson, and J.-W. de Gier, “Tuning Escherichia coli for membrane
protein overexpression ,” Proceedings of the National Academy of Sciences, vol. 105, no. 38,
p. 14371, 2008.
[73] M. J. Giacalone, A. M. Gentile, B. T. Lovitt, N. L. Berkley, C. W. Gunderson, and M. W. Surber,
“Toxic protein expression in Escherichia coli using a rhamnose-based tightly regulated and tun-
able promoter system,” BioTechniques, vol. 40, no. 3, pp. 355–364, 2006.
[74] H. P. Sørensen and K. K. Mortensen, “Advanced genetic strategies for recombinant protein ex-
pression in Escherichia coli,” Journal of Biotechnology, vol. 115, no. 2, pp. 113–128, 2005.
[75] J. W. Dubendorf and F. W. Studier, “Controlling basal expression in an inducible T7 expression
system by blocking the target T7 promoter with lac repressor,” Journal of Molecular Biology,
vol. 219, no. 1, pp. 45–59, 1991.
102
BIBLIOGRAPHY
[76] M. P. Calos, “DNA sequence for a low-level promoter of the lac repressor gene and an ‘up’
promoter mutation,” Nature, vol. 274, no. 5673, pp. 762–765, 1978.
[77] S. Costa, A. Almeida, A. Castro, and L. Domingues, “Fusion tags for protein solubility, purifica-
tion and immunogenicity in Escherichia coli: the novel Fh8 system,” Frontiers in Microbiology,
vol. 5, no. 63, 2014.
[78] D. S. Waugh, “An overview of enzymatic reagents for the removal of affinity tags,” Protein
expression and purification, vol. 80, no. 2, pp. 283–293, 2011.
[79] J. M. Jez, J.-L. Ferrer, M. E. Bowman, R. A. Dixon, and J. P. Noel, “Dissection of Malonyl-
Coenzyme A Decarboxylation from Polyketide Formation in the Reaction Mechanism of a Plant
Polyketide Synthase,” Biochemistry, vol. 39, no. 5, pp. 890–902, 2000.
[80] J. M. Hsieh, G. M. Besserer, M. G. Madej, H.-Q. Bui, S. Kwon, and J. Abramson, “Bridging the
gap: a GFP-based strategy for overexpression and purification of membrane proteins with intra
and extracellular C-termini,” Protein science : a publication of the Protein Society, vol. 19, no. 4,
pp. 868–880, 2010.
[81] A. L. Throop and J. LaBaer, “Site-specific recombinational cloning using gateway and in-fusion
cloning schemes,” Current protocols in molecular biology, vol. 110, pp. 3.20.1–3.20.23, 2015.
[82] Novagen pET System Manual. Merck KGaA, Darmstadt, Germany, User Protocol TB055 Rev.
C 0611J, 11th ed., 2011.
[83] EMBL, “Protein expression and purification core facility,” 2019. Available at:
https://www.embl.de/pepcore/pepcore_services/index.html.
[84] Strategies for Protein Purification. Uppsala: GE Healthcare Bio-Sciences AB, 2010.
[85] J. A. Bornhorst and J. J. Falke, “Purification of proteins using polyhistidine affinity tags,” Meth-
ods in enzymology, vol. 326, pp. 245–254, 2000.
[86] H. Block, B. Maertens, A. Spriestersbach, N. Brinker, J. Kubicek, R. Fabis, J. Labahn, and
F. Schäfer, Chapter 27 Immobilized-Metal Affinity Chromatography (IMAC): A Review, vol. 463,
pp. 439–473. Academic Press, 2009.
[87] S. Fekete, A. Beck, J.-L. Veuthey, and D. Guillarme, “Theory and practice of size exclusion chro-
matography for the analysis of protein aggregates,” Journal of Pharmaceutical and Biomedical
Analysis, vol. 101, pp. 161–173, 2014.
[88] A. L. Shapiro, E. Viñuela, and J. V. Maizel, “Molecular weight estimation of polypeptide chains
by electrophoresis in SDS-polyacrylamide gels,” Biochemical and Biophysical Research Com-
munications, vol. 28, no. 5, pp. 815–820, 1967.
103
BIBLIOGRAPHY
[89] J. M. Walker, The Bicinchoninic Acid (BCA) Assay for Protein Quantitation, pp. 11–14. Totowa,
NJ: Humana Press, 2002.
[90] E. Gasteiger, C. Hoogland, A. Gattiker, S. Duvaud, M. R. Wilkins, R. D. Appel, and A. Bairoch,
Protein Identification and Analysis Tools on the ExPASy Server, pp. 571–607. Totowa, NJ: Hu-
mana Press, 2005.
[91] C. The UniProt, “UniProt: a worldwide hub of protein knowledge,” Nucleic Acids Research,
vol. 47, no. D1, pp. D506–D515, 2018.
[92] T. W. Chang, “Binding of cells to matrixes of distinct antibodies coated on solid surface,” J
Immunol Methods, vol. 65, no. 1-2, pp. 217–23, 1983.
[93] P. V. Pham, Chapter 19 - Medical Biotechnology: Techniques and Applications, pp. 449–469.
Academic Press, 2018.
[94] M. Abdollahzadeh, M. S. Saidi, and A. Sadeghi, “Enhancement of surface adsorption-desorption
rates in microarrays invoking surface charge heterogeneity,” Sensors and Actuators B: Chemical,
vol. 242, pp. 956–964, 2017.
[95] A. L. Furst, S. H. Klass, and M. B. Francis, “DNA Hybridization to Control Cellular Interac-
tions,” Trends in Biochemical Sciences, 2018.
[96] M. Schena, D. Shalon, R. W. Davis, and P. O. Brown, “Quantitative monitoring of gene expres-
sion patterns with a complementary DNA microarray,” Science, vol. 270, no. 5235, pp. 467–70,
1995.
[97] M. B. Miller and Y. W. Tang, “Basic concepts of microarrays and potential applications in clinical
microbiology,” Clin Microbiol Rev, vol. 22, no. 4, pp. 611–33, 2009.
[98] M. P. . V. M. López M., “Microarrays y Biochips de ADN. ,” Informe de Vigilancia Tecnológica,
no. GEN-ES02001, p. 56, 2002.
[99] R. Frank, “Spot-synthesis: an easy technique for the positionally addressable, parallel chemical
synthesis on a membrane support,” Tetrahedron, vol. 48, no. 42, pp. 9217–9232, 1992.
[100] E. M. Cornett, B. M. Dickson, R. M. Vaughan, S. Krishnan, R. C. Trievel, B. D. Strahl, and
S. B. Rothbart, Chapter Two - Substrate Specificity Profiling of Histone-Modifying Enzymes by
Peptide Microarray, vol. 574, pp. 31–52. Academic Press, 2016.
[101] S. B. Rothbart, K. Krajewski, B. D. Strahl, and S. M. Fuchs, “Peptide microarrays to interrogate
the "histone code",” Methods Enzymol, vol. 512, pp. 107–35, 2012.
[102] V. Stadler, T. Felgenhauer, M. Beyer, S. Fernandez, K. Leibe, S. Guttler, M. Groning, K. Konig,
G. Torralba, M. Hausmann, V. Lindenstruth, A. Nesterov, I. Block, R. Pipkorn, A. Poustka, F. R.
Bischoff, and F. Breitling, “Combinatorial synthesis of peptide arrays with a laser printer,” Angew
Chem Int Ed Engl, vol. 47, no. 37, pp. 7132–5, 2008.
104
BIBLIOGRAPHY
[103] C. Ludwig, Diffusion zwischen ungleich erwärmten Orten gleich zusammengesetzter Lösung.
Aus der K.K. Hof- und Staatsdruckerei, in Commission bei W. Braumüller, Buchhändler des
K.K. Hofes und der K. Akademie der Wissenschaften, 1856.
[104] M. Jerabek-Willemsen, C. J. Wienken, D. Braun, P. Baaske, and S. Duhr, “Molecular interac-
tion studies using microscale thermophoresis,” Assay and drug development technologies, vol. 9,
no. 4, pp. 342–353, 2011.
[105] C. J. Wienken, P. Baaske, U. Rothbauer, D. Braun, and S. Duhr, “Protein-binding assays in bio-
logical liquids using microscale thermophoresis,” Nature Communications, vol. 1, p. 100, 2010.
[106] M. Jerabek-Willemsen, T. André, R. Wanner, H. M. Roth, S. Duhr, P. Baaske, and D. Breit-
sprecher, “MicroScale Thermophoresis: Interaction analysis and beyond,” Journal of Molecular
Structure, vol. 1077, pp. 101–113, 2014.
[107] S. A. I. Seidel, P. M. Dijkman, W. A. Lea, G. van den Bogaart, M. Jerabek-Willemsen, A. Lazic,
J. S. Joseph, P. Srinivasan, P. Baaske, A. Simeonov, I. Katritch, F. A. Melo, J. E. Ladbury,
G. Schreiber, A. Watts, D. Braun, and S. Duhr, “Microscale thermophoresis quantifies biomolec-
ular interactions under previously challenging conditions,” Methods (San Diego, Calif.), vol. 59,
no. 3, pp. 301–315, 2013.
[108] Y. Mao, L. Yu, R. Yang, L.-b. Qu, and P. d. B. Harrington, “A novel method for the study
of molecular interaction by using microscale thermophoresis,” Talanta, vol. 132, pp. 894–901,
2015.
[109] MST StartingGuide –Monolith NT.115. Munich: NanoTemper Technologies GmbH.
[110] U. B. Ericsson, B. M. Hallberg, G. T. DeTitta, N. Dekker, and P. Nordlund, “Thermofluor-based
high-throughput stability optimization of proteins for structural studies,” Analytical Biochem-
istry, vol. 357, no. 2, pp. 289–298, 2006.
[111] M.-C. Lo, A. Aulabaugh, G. Jin, R. Cowling, J. Bard, M. Malamas, and G. Ellestad, “Evaluation
of fluorescence-based thermal shift assays for hit identification in drug discovery,” Analytical
Biochemistry, vol. 332, no. 1, pp. 153–159, 2004.
[112] M. K. Groftehauge, N. R. Hajizadeh, M. J. Swann, and E. Pohl, “Protein-ligand interactions
investigated by thermal shift assays (TSA) and dual polarization interferometry (DPI),” Acta
Crystallographica Section D, vol. 71, no. 1, pp. 36–44, 2015.
[113] G. V. Semisotnov, N. A. Rodionova, O. I. Razgulyaev, V. N. Uversky, A. F. Gripas’, and R. I.
Gilmanshin, “Study of the “molten globule” intermediate state in protein folding by a hydropho-
bic fluorescent probe,” Biopolymers, vol. 31, no. 1, pp. 119–128, 1991.
[114] J. J. Lavinder, S. B. Hari, B. J. Sullivan, and T. J. Magliery, “High-Throughput Thermal Scanning:
A General, Rapid Dye-Binding Thermal Shift Screen for Protein Engineering,” Journal of the
American Chemical Society, vol. 131, no. 11, pp. 3794–3795, 2009.
105
BIBLIOGRAPHY
[115] K. Huynh and C. L. Partch, “Analysis of protein stability and ligand interactions by thermal shift
assay,” Current protocols in protein science, vol. 79, pp. 28.9.1–28.9.14, 2015.
[116] F. H. Niesen, H. Berglund, and M. Vedadi, “The use of differential scanning fluorimetry to detect
ligand interactions that promote protein stability,” Nature Protocols, vol. 2, p. 2212, 2007.
[117] F. Vollrath, N. Hawkins, D. Porter, C. Holland, and M. Boulet-Audet, “Differential Scanning
Fluorimetry provides high throughput data on silk protein transitions,” Scientific Reports, vol. 4,
p. 5625, 2014.
[118] “The Nobel Prize in Chemistry 2012,” 2019. Available at:
https://www.nobelprize.org/prizes/chemistry/2012/summary/.
[119] B. Rupp, Biomolecular Crystallography: Principles, Practice, and Application to Structural Bi-
ology. Garland Science, 2009.
[120] C. Giacovazzo, H. Monaco, G. Artioli, D. Viterbo, G. Ferraris, G. Gilli, G. Zanotti, and M. Catti,
Fundamentals of Crystallography. New York: Oxford University Press, 2002.
[121] G. Rhodes, Crystallography Made Crystal Clear. Burlington: Academic Press, 2006.
[122] N. Asherie, “Protein crystallization and phase diagrams,” Methods, vol. 34, no. 3, pp. 266–272,
2004.
[123] A. McPherson and J. A. Gavira, “Introduction to protein crystallization,” Acta crystallographica.
Section F, Structural biology communications, vol. 70, no. Pt 1, pp. 2–20, 2014.
[124] W. H. Bragg and W. L. Bragg, “The reflection of X-rays by crystals,” Proceedings of the Royal
Society of London. Series A, Containing Papers of a Mathematical and Physical Character,
vol. 88, no. 605, pp. 428–438, 1913.
[125] Martinez-Ripoll, “Csic-crystallography,” 2018. Available at:
http://www.xtal.iqfr.csic.es/Cristalografia/welcome-en.html.
[126] G. Taylor, “The phase problem,” Acta Crystallographica Section D, vol. 59, no. 11, pp. 1881–
1890, 2003.
[127] P. Evans and A. McCoy, “An introduction to molecular replacement,” Acta crystallographica.
Section D, Biological crystallography, vol. 64, no. Pt 1, pp. 1–10, 2008.
[128] D. D. Rodríguez, C. Grosse, S. Himmel, C. González, I. M. de Ilarduya, S. Becker, G. M.
Sheldrick, and I. Usón, “Crystallographic ab initio protein structure solution below atomic reso-
lution,” Nature Methods, vol. 6, p. 651, 2009.
[129] I. Caballero, M. Sammito, C. Millan, A. Lebedev, N. Soler, and I. Uson, “ARCIMBOLDO on
coiled coils,” Acta Crystallographica Section D, vol. 74, no. 3, pp. 194–204, 2018.
106
BIBLIOGRAPHY
[130] S. Hovmöller, Rotation Matrices and Translation Vectors in Crystallography. Walles: Interna-
tional Union of Crystallography, University College Cardiff Press, 1981.
[131] E. A. Merritt, “X-ray anomalous scattering,” 2012. Available at:
http://skuld.bmsc.washington.edu/scatter/AS_index.html.
[132] R. J. Read and A. J. McCoy, “Using SAD data in Phaser,” Acta crystallographica. Section D,
Biological crystallography, vol. 67, no. Pt 4, pp. 338–344, 2011.
[133] W. A. Hendrickson, “Determination of macromolecular structures from anomalous diffraction of
synchrotron radiation,” Science, vol. 254, no. 5028, p. 51, 1991.
[134] K. D. Cowtan and K. Y. J. Zhang, “Density modification for macromolecular phase improve-
ment,” Progress in Biophysics and Molecular Biology, vol. 72, no. 3, pp. 245–270, 1999.
[135] A. Balerna and S. Mobilio, Introduction to Synchrotron Radiation, pp. 3–28. Berlin, Heidelberg:
Springer Berlin Heidelberg, 2015.
[136] H. Toyokawa, C. Broennimann, E. F. Eikenberry, B. Henrich, M. Kawase, M. Kobas, P. Kraft,
M. Sato, B. Schmitt, M. Suzuki, H. Tanida, and T. Uruga, “Single photon counting pixel detectors
for synchrotron radiation experiments,” Nuclear Instruments and Methods in Physics Research
Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, vol. 623, no. 1,
pp. 204–206, 2010.
[137] H. R. Powell, “X-ray data processing,” Bioscience reports, vol. 37, no. 5, p. BSR20170227, 2017.
[138] P. R. Evans and G. N. Murshudov, “How good are my data and what is the resolution?,” Acta
Crystallographica Section D, vol. 69, no. 7, pp. 1204–1214, 2013.
[139] A. G. W. Leslie and H. R. Powell, “Processing diffraction data with mosflm,” in Evolving
Methods for Macromolecular Crystallography (R. J. Read and J. L. Sussman, eds.), pp. 41–51,
Springer Netherlands.
[140] W. Kabsch, “XDS,” Acta Crystallographica Section D, vol. 66, no. 2, pp. 125–132, 2010.
[141] P. A. Karplus and K. Diederichs, “Assessing and maximizing data quality in macromolecular
crystallography,” Current opinion in structural biology, vol. 34, pp. 60–68, 2015.
[142] P. D. Adams, P. V. Afonine, G. Bunkoczi, V. B. Chen, I. W. Davis, N. Echols, J. J. Headd, L.-W.
Hung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W. Moriarty, R. Oeffner, R. J.
Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger, and P. H. Zwart, “PHENIX: a com-
prehensive Python-based system for macromolecular structure solution,” Acta Crystallographica
Section D, vol. 66, no. 2, pp. 213–221, 2010.
107
BIBLIOGRAPHY
[143] A. J. McCoy, R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni, and R. J. Read,
“Phaser crystallographic software,” Journal of Applied Crystallography, vol. 40, no. 4, pp. 658–
674, 2007.
[144] T. C. Terwilliger, P. D. Adams, R. J. Read, A. J. McCoy, N. W. Moriarty, R. W. Grosse-Kunstleve,
P. V. Afonine, P. H. Zwart, and L.-W. Hung, “Decision-making in structure solution using
Bayesian estimates of map quality: the PHENIX AutoSol wizard,” Acta Crystallographica Sec-
tion D, vol. 65, no. 6, pp. 582–601, 2009.
[145] T. C. Terwilliger, R. W. Grosse-Kunstleve, P. V. Afonine, N. W. Moriarty, P. H. Zwart, L.-W.
Hung, R. J. Read, and P. D. Adams, “Iterative model building, structure refinement and density
modification with the PHENIX AutoBuild wizard,” Acta Crystallographica Section D, vol. 64,
no. 1, pp. 61–69, 2008.
[146] P. V. Afonine, R. W. Grosse-Kunstleve, N. Echols, J. J. Headd, N. W. Moriarty, M. Mustyakimov,
T. C. Terwilliger, A. Urzhumtsev, P. H. Zwart, and P. D. Adams, “Towards automated crystal-
lographic structure refinement with phenix.refine,” Acta Crystallographica Section D, vol. 68,
no. 4, pp. 352–367, 2012.
[147] V. B. Chen, I. Arendall, W. Bryan, J. J. Headd, D. A. Keedy, R. M. Immormino, G. J. Kapral,
L. W. Murray, J. S. Richardson, and D. C. Richardson, “MolProbity: all-atom structure validation
for macromolecular crystallography,” Acta Crystallographica Section D, vol. 66, no. 1, pp. 12–
21, 2010.
[148] P. Emsley, B. Lohkamp, W. G. Scott, and K. Cowtan, “Features and development of Coot,” Acta
Crystallographica Section D, vol. 66, no. 4, pp. 486–501, 2010.
[149] C. D. Putnam, M. Hammel, G. L. Hura, and J. A. Tainer, “X-ray solution scattering (SAXS) com-
bined with crystallography and computation: defining accurate macromolecular structures, con-
formations and assemblies in solution,” Quarterly Reviews of Biophysics, vol. 40, no. 3, pp. 191–
285, 2007.
[150] H. D. T. Mertens and D. I. Svergun, “Structural characterization of proteins and complexes using
small-angle X-ray solution scattering,” Journal of Structural Biology, vol. 172, no. 1, pp. 128–
141, 2010.
[151] A. G. Kikhney and D. I. Svergun, “A practical guide to small angle X-ray scattering (SAXS) of
flexible and intrinsically disordered proteins,” FEBS Letters, vol. 589, no. 19PartA, pp. 2570–
2577, 2015.
[152] A. Guinier, “La diffraction des rayons X aux très petits angles : application à l’étude de
phénomènes ultramicroscopiques,” Ann. Phys., vol. 11, no. 12, pp. 161–237, 1939.
108
BIBLIOGRAPHY
[153] J. Trewhella, A. P. Duff, D. Durand, F. Gabel, J. M. Guss, W. A. Hendrickson, G. L. Hura, D. A.
Jacques, N. M. Kirby, A. H. Kwan, J. Pérez, L. Pollack, T. M. Ryan, A. Sali, D. Schneidman-
Duhovny, T. Schwede, D. I. Svergun, M. Sugiyama, J. A. Tainer, P. Vachette, J. Westbrook, and
A. E. Whitten, “2017 publication guidelines for structural modelling of small-angle scattering
data from biomolecules in solution: an update,” Acta crystallographica. Section D, Structural
biology, vol. 73, no. Pt 9, pp. 710–728, 2017.
[154] M. E. Brennich, J. Kieffer, G. Bonamis, A. De Maria Antolinos, S. Hutin, P. Pernot, and
A. Round, “Online data analysis at the ESRF bioSAXS beamline, BM29,” Journal of Applied
Crystallography, vol. 49, no. 1, pp. 203–212, 2016.
[155] D. Franke, M. V. Petoukhov, P. V. Konarev, A. Panjkovich, A. Tuukkanen, H. D. T. Mertens,
A. G. Kikhney, N. R. Hajizadeh, J. M. Franklin, C. M. Jeffries, and D. I. Svergun, “ATSAS 2.8:
a comprehensive data analysis suite for small-angle scattering from macromolecular solutions,”
Journal of applied crystallography, vol. 50, no. Pt 4, pp. 1212–1225, 2017.
[156] P. V. Konarev, V. V. Volkov, A. V. Sokolova, M. H. J. Koch, and D. I. Svergun, “PRIMUS: a
Windows PC-based system for small-angle scattering data analysis,” Journal of Applied Crystal-
lography, vol. 36, no. 5, pp. 1277–1282, 2003.
[157] D. Franke and D. I. Svergun, “DAMMIF, a program for rapid ab-initio shape determination in
small-angle scattering,” Journal of applied crystallography, vol. 42, no. Pt 2, pp. 342–346, 2009.
[158] V. V. Volkov and D. I. Svergun, “Uniqueness of ab initio shape determination in small-angle
scattering,” Journal of Applied Crystallography, vol. 36, no. 3 Part 1, pp. 860–864, 2003.
[159] D. Svergun, C. Barberato, and M. H. J. Koch, “CRYSOL - a Program to Evaluate X-ray So-
lution Scattering of Biological Macromolecules from Atomic Coordinates,” Journal of Applied
Crystallography, vol. 28, no. 6, pp. 768–773, 1995.
[160] J. VanderPlas, Frequentism and Bayesianism: A Python-driven Primer. 2014.
[161] N. Gutierrez A., Metodos Bayesianos en Estadistica Oficial. 2017.
[162] W. M. Bolstad, Introduction to Bayesian Statistics. Wiley-Blackwell, 2nd ed., 2007.
[163] T. Bayes and n. Price, “LII. An essay towards solving a problem in the doctrine of chances. By
the late Rev. Mr. Bayes, F. R. S. communicated by Mr. Price, in a letter to John Canton, A. M. F.
R. S,” Philosophical Transactions of the Royal Society of London, vol. 53, pp. 370–418, 1763.
[164] A. Landro and M. González, “BERNOULLI, DE MOIVRE, BAYES, PRICE Y LOS FUNDA-
MENTOS DE LA INFERENCIA INDUCTIVA,” Cuadernos del CIMBAGE, vol. 15, pp. 33–56,
2013.
[165] J. L. Devore, Probability and Statistics for Engineering and the Sciences. Belmont: Broks Cole
Publishing Co, 6th ed., 2004.
109
BIBLIOGRAPHY
[166] K. Pearson, R. A. Fisher, and H. F. Inman, “Karl Pearson and R. A. Fisher on Statistical Tests: A
1935 Exchange from Nature,” The American Statistician, vol. 48, no. 1, pp. 2–11, 1994.
[167] C. B. Boyer, A History of Mathematics. New York, United States: Wiley International Edition,
1968.
[168] A. Etz, “Introduction to the Concept of Likelihood and Its Applications,” Advances in Methods
and Practices in Psychological Science, vol. 1, no. 1, pp. 60–69, 2018.
[169] L. J. Bain and M. Engelhardt, Introduction To Probability And Mathematical Statistics. Boston:
Duxbury Press, 1987.
[170] G. Grimmett and D. Welsh, PROBABILITY. An Introduction. Oxford Science Publications, 1990.
[171] A. Eshky, “Bayesian methods of parameter estimation,” University of Edinburgh, School of In-
formatics, 2008.
[172] C. Davidson-Pilon, Bayesian Methods for Hackers: Probabilistic Programming and Bayesian
Inference. Addison-Wesley, 2015.
[173] D. J. Spiegelhalter, K. R. Abrams, and J. P. Myles, Bayesian Approaches To Clinical Trials And
Health-Care Evaluation. John Wiley and Sons, Ltd, 2004.
[174] T. Schweder and N. L. Hjort, Confidence, Likelihood, Probability: Statistical Inference with Con-
fidence Distributions. Cambridge Series in Statistical and Probabilistic Mathematics, Cambridge:
Cambridge University Press, 2016.
[175] D. Lewandowski, D. Kurowicka, and H. Joe, Generating random correlation matrices based on
vines and extended onion method, vol. 100. 2009.
[176] T. H. Scheuermann, S. B. Padrick, K. H. Gardner, and C. A. Brautigam, “On the acquisition and
analysis of microscale thermophoresis data,” Analytical Biochemistry, vol. 496, pp. 79–93, 2016.
[177] L. Reinhard, H. Mayerhofer, A. Geerlof, J. Mueller-Dieckmann, and M. S. Weiss, “Optimiza-
tion of protein buffer cocktails using Thermofluor,” Acta crystallographica. Section F, Structural
biology and crystallization communications, vol. 69, no. Pt 2, pp. 209–214, 2013.
[178] N. R. Hajizadeh, D. Franke, C. M. Jeffries, and D. I. Svergun, “Consensus Bayesian assessment
of protein molecular mass from solution X-ray scattering data,” Scientific Reports, vol. 8, no. 1,
p. 7204, 2018.
[179] B. Rost and C. Sander, “Prediction of Protein Secondary Structure at Better than 70% Accuracy,”
Journal of Molecular Biology, vol. 232, no. 2, pp. 584–599, 1993.
[180] S. Chojnacki, A. Cowley, J. Lee, A. Foix, and R. Lopez, “Programmatic access to bioinformatics
tools from EMBL-EBI update: 2017,” Nucleic Acids Research, vol. 45, no. W1, pp. W550–
W553, 2017.
110
